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Inspired pollutants have been associated with an increased risk of developing 
respiratory and cardiovascular diseases. While epidemiological studies have attempted to 
elucidate potential correlations, few have been able to determine true impacts of the 
pollutants much less elucidate a mechanism of action. The purpose of this thesis is to 
disseminate the knowledge of previously collected data pertaining to inspired pollutants 
including: the effects of formaldehyde (FA) on pulmonary function, the effects of FA on 
vascular function, and the effect of electronic cigarettes on metabolic and ventilatory 
measurements during exercise. As an added measure to the FA manuscripts, biomarkers of 
oxidative stress and inflammation were assess immediately prior to and following an acute 
exposure to FA which has potential to reveal a mechanism. While FA influence the 
vasculature, pulmonary function remained unchanged as a percent difference from pre-FA 
exposure. Additionally, no physiological differences were observed in males comparing a 
placebo incremental exercise test to an experimental electronic cigarette incremental exercise 
test. In essence, inspired pollutants may damage otherwise young and healthy individuals; 
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Foreword 
The content of this thesis is intended to be submitted for publication in two different journals. 
The first manuscript, entitled “Vascular Dysfunction and Oxidative Stress Caused by Acute 
Formaldehyde Exposure in Female Adults,” has been accepted to the American Journal of 
Physiology: Heart and Circulatory Physiology. The second manuscript, entitled “Pulmonary Function 
Following Acute Formaldehyde Exposure in Young Adults,” is written to be submitted to the Journal 
of Environmental Toxicology. The third manuscript, entitled “Metabolic and Ventilatory Responses to 
Exercise Following Electronic Cigarette Usage,” is intended to be submitted to the Journal of 
Environmental Toxicology. All manuscripts have been formatted according to their respective journal 
regulations. Additionally, all written work aiding to the background of this thesis has been formatted 
to the American Journal of Applied Physiology: Heart and Circulatory Physiology. The background 
information for this document will have references found at the end of the document; however, each 
manuscript will maintain its own reference section within its respective chapter.  
Chapter 1 
The contents of this thesis document are composed to satisfy requirements set forth. The 
committee have agreed that the required materials are three manuscripts with a central topic based on 
environmental pollutants and how they may influence respiratory or cardiovascular physiology. Given 
the deviation from a typical thesis format, the format of this document is intended to display the topics 
as individual manuscripts with their respective measures and pollutants, while keeping the 
formaldehyde background and manuscripts together in Chapter 2 and Chapter 3 comprising electronic 
cigarette background and manuscript. The first manuscript of Chapter 2 is entitled Vascular 
Dysfunction and Oxidative Stress Caused by Acute Formaldehyde Exposure in Female Adults which 
measures the effect formaldehyde has on the vasculature as well as compared pre- and post- exposure 
biomarkers of oxidative stress to attempt to elucidate a mechanism. Second is a manuscript entitled 
Pulmonary Function Following Acute Formaldehyde Exposure in Young Adults which assesses the 
effect of formaldehyde on pulmonary function. The two manuscripts of Chapter 2 I had part in 
composing the study design, data collection and organization, statistical analysis, manuscript 
composition and creation of figures. Finally, the third manuscript entitled Metabolic and Ventilatory 
Responses to Exercise Following Electronic Cigarette Usage exposes subjects to electronic cigarette 
vapor, or placebo, to assess if responses to exercise are diminished or amplified. The manuscript of 
Chapter 3 I had the opportunity to process data, statistically analyze said data, compose a manuscript 
and creation of figures. 
These three manuscripts are centered on the concept that an inspirate, both naturally occurring 
formaldehyde and synthesized electronic cigarette vapor, have the potential to influence tissues of the 
respiratory system. In the event that the environmental pollutants (EP) are small enough, there is 
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potential for the inspirate to cross the alveolar membrane into the blood stream where vasculature can 
be influenced. These manuscripts combine respiratory characteristics with cardiovascular physiology 
to disseminate the integrative nature of these systems. 
The study of human physiology has long been of interest so much so that prediction equations 
have been established to determine when individuals deviate from expected values, potentially pointing 
to a physiological impairment. For example, Wasserman developed equations to determine the minute 
volume of consumed oxygen against no resistance as well as at peak exercise in humans on a cycle 
ergometer (1) and is the foundation for articles that look at deviations from expected in clinical 
populations (2). 
When observing metabolic parameters of rest, regression equations have been established by 
observing heat production (3): 
Male: ℎ = 66.4730 + 13.7516 (𝑘𝑘𝑘𝑘) + 5.0033 (𝑐𝑐𝑐𝑐)− 6.7550 (𝑦𝑦𝑦𝑦) 
Female: ℎ = 655.0955 + 9.5634 (𝑘𝑘𝑘𝑘) + 1.8496 (𝑐𝑐𝑐𝑐)− 4.6756 (𝑦𝑦𝑦𝑦) 
with knowledge that sex, height, weight and age having an effect on resting metabolic rate, there must 
be acknowledgement that factors beyond human control influence metabolic rate including oxidative 
stress from hydrogen peroxide and superoxide (4). Furthermore, the same principles can be extrapolated 
to exercise. Again, the Wasserman equations are intended to predict V̇O2max of otherwise healthy 
individuals (2): 
Male: ?̇?𝑉𝑂𝑂2 (𝑐𝑐𝑚𝑚 ∙ 𝑐𝑐𝑚𝑚𝑚𝑚−1) = 𝑊𝑊 [ 50.75− 0.372(𝐴𝐴)] 
Female: ?̇?𝑉𝑂𝑂2 (𝑐𝑐𝑚𝑚 ∙ 𝑐𝑐𝑚𝑚𝑚𝑚−1) = (𝑊𝑊 − 43) [22.78− 0.17(𝐴𝐴)] 
where W is mass in kilograms and A is age in years. It should be noted that updated equations have 
been published by Wasserman and colleagues in 1999. Given this information, it can be assumed that 
oxidative stress incurred from EP will eventually lead to increases in metabolic rate thus altering the 
normal homeostatic conditions of systems.  
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In healthy individuals, measurements from an incremental exercise test such as the proportional 
increases of heart rate and V̇O2 (5) can elucidate the physiological principles at the recorded time frame. 
Ventilation (V̇E) has two inflections to the trend line in which correlate to the aerobic threshold and the 
anaerobic threshold as work rate (WR) increases towards subject V̇O2max (6, 7). The second inflection 
of the ventilation line where V̇E increases disproportionately to WR is labeled the anaerobic threshold 
and is hyperventilation relative to oxygen consumption (6, 8, 9). 
When observing the metabolic responses to an incremental exercise test, specific variables are 
assessed for their likeness to normal trends, for instance resting respiratory exchange ratio (RER) is 
expected to be approximately 0.70 as lipids are the primary metabolite at rest as aerobic metabolism 
has the largest adenosine triphosphate (ATP) production per energy investment (10). The RER is the 
minute volume of produced carbon dioxide (V̇CO2) and the minute volume consumed oxygen (V̇O2); 
due to the beta oxidation of fatty acids, most commonly palmitoyl-stearoyl-oleoyl-glycerol in human 
adipose tissue (11), to acetyl-CoA, and further reactions via the Krebs Cycle, the overall combustion 
reaction results in a V̇CO2 = 1.427 L and V̇O2 = 2.019 L, thus an RER = 0.707. Additionally, there is a 
shift in metabolism from lipid oxidation to greater carbohydrate metabolism which is anaerobic during 
glycolysis (10) and has a lower oxygen consumption during oxidations (0.746 mL∙g-1) and equivalent 
production of carbon dioxide (0.746 mL∙g-1) thus an RER value of 1.00 (11). In a system similar to 
Simonson & DeFronzo (1990), in vitro experiments would reach a ceiling value and is described as the 
respiratory quotient (RQ = 1.00); however, in vivo experiments measure gas volumes at the mouth and 
is influenced by the dynamics of the respiratory system with maintaining homeostasis. At high work 
rates, such as those in an incremental exercise test, the respiratory system is responsible for maintaining 
blood pH by hyperventilating to buffer for the increasing proton concentration by freeing bicarbonate 
(12). To summarize, in vivo experiments measure the V̇CO2 produced and the V̇O2 consumed and 
express the value as a ratio (RER) which can be greater than 1.00 due to buffering via respiratory 
system. 
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The breathing mechanics of normal exercise describes the pressures generated, the flow and 
volume of air. The assessment of breathing mechanics requires that lung volumes and spirometry are 
measured as these values complete the picture when assessing for variables such as expiratory flow 
limitation. A normal response to exercise is for the end-inspiratory lung volume (EILV) to increase 
from rest with each increase of WR (13) whereas end-expiratory lung volume (EELV) decreases 
slightly from resting EELV (13). These changes in volumes can be integrated to a single volume, tidal 
volume (VT), though this is limited as the inspiratory and expiratory reserves are not accounted for in 
VT. Additionally, the duration of inspiration and expiration (Ti and Te, respectively) are observed as a 
function of flow and made relative to the total duration of a breath (Ttot) (14). Durations of breaths are 
expected to have a longer duration during expiration as the act of expiration is passive, until high 
breathing frequency (ƒB) is required; conversely, inspiration requires contraction of the diaphragm and 
additional trunk muscles at higher VT. Therefore, relative to Ttot, Ti tends to be <0.50 and Te >0.50 both 
at rest and moderate V̇E (15). Furthermore, increasing WR causes the Ti/Ttot and Te/Ttot to converge 
closer to 0.50 suggesting that Ti/Te are equivalent (15).  
A purpose for the measurement of breathing mechanics is expiratory flow limitation (EFL) 
(16). When overlaying a tidal breath on a maximal flow volume loop (FVL), an EFL can be observed 
as an overlap of the tidal and maximal FVL (tFVL and mFVL, respectively) (17). However, EFL can 
be described by transpulmonary pressures as certain pressures at given volumes did not increase flow 
(16).  
Much of cardiopulmonary function is made relative to the subject, one set of variables being 
the pulmonary function (2). As suggested by Johnson et al. (17), V̇E relative to maximum voluntary 
ventilation (MVV) is lesser of a predictor of ventilatory constraints than that of EFL. Additionally, the 
mFVL is used from measures of spirometry in the assessment of EFL (17). The mFVL along with lung 
volume assessments, via body plethysmography observing Boyles Law or nitrogen/helium washouts 
(18), are essential in describing operational lung volumes and assessing the breathing mechanics during 
rest and exercise (19). 
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As for vascular assessments, flow-mediated dilation (FMD) has been established as a 
measurement of vascular health in large part due to the relationship between brachial artery dilation 
and coronary dilation capabilities (20) as well as indices for atherosclerotic events (21). The rationale 
behind FMD is that, with brachial artery having a relationship with coronary arteries, shear stress 
induces nitric oxide (NO) release (22) thus dilating vessels. In healthy persons, FMD is expected to be 
a higher percentage (7-18 %) than those of smokers (-1-17 %) and coronary artery disease individuals 
(-6-7 %) (21) which suggests that individuals that have been exposed to higher oxidative stress, such 
as smoking (23), may have impaired vascular function.  
Additionally, the measure of reactive hyperemia is assessed simultaneously with FMD 
measures and aids to measure vascular resistance (24). This further plays off the principle that NO is 
essential to endothelial function as it reduces resistance by increasing diameter (21). 
The variables concerning exercise metabolism, ventilatory dynamics, and vascular function, 
are what can be expected from otherwise healthy adults; however, EP can play a crucial role in the 
regulation of these variables. 
Human physiology is a highly integrative topic that spans beyond that of just internal systems. 
Basic knowledge suggests that the environmental conditions in which organisms reside will influence 
that organism; however, to what extent, the mechanisms of action, and the likelihood of exposure to 
certain stimuli tends to be a far more intricate topic of discussion. Studies have gone as far to suggest 
a correlation of environmental pollution (EP) to that of disease risk such as metabolic syndromes (25, 
26), chronic obstructive pulmonary disease (27-29), or even cardiovascular disease (25, 30). Given 
these suggestions, the mechanisms of disease are necessities to prevention in lieu of treatment or to 
slow progression at the least. Commonly, EP initiate oxidative stress (30, 31) which, in turn, alters the 
normal cellular function of tissues as redox reactions occur within all cells (32).  
Contrary to initial thoughts of what EP can be, natural chemicals such as formaldehyde (FA) 
as well as cigarette smoke, which can contain particulate matter (33), are considered air EP. Given the 
gaseous form of the aforementioned EP, potential for exposure to the pollutants is increased as they 
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dilute into fluids (34). With exposure of EP being gaseous, inhalation causes the respiratory system to 
be readily insulted (35) as well as diffuse EP into the blood (36) and increase oxidative stress (31, 37-
41). Commonly, oxidative stress is induced by free radicals which later affects lipid and protein 
structures (31). Therefore, assessment of human physiology is essential to understanding how the 
correlations between EP and chronic disease are possible and how it is that humans may be affected so 











Formaldehyde (FA) is a Group 1 carcinogen that has many applications in the preservation of 
biological materials given its fungicidal and bactericidal properties (42). While FA has many 
applications, the simplicity and size tend to allow for FA to disrupt protein and membrane organization. 
Therefore, the likelihood of FA disturbing human cells appears to be likely seeing as how the chemical 
can diffuse through mucosal membranes. Additionally, FA is found in either a liquid solution, known 
as formalin, or as a volatile organic compound in the air being breathed. The inspiration of FA has been 
known to cause irritation of the epithelial linings of the airways (39, 43) further suggesting that damage 
is incurred by FA inspiration. 
The solution to preserving materials is, there in, the problem to basic physiological function. 
To gain perspective, hypothesis testing on experimental procedures would elucidate on the extent to 
which normal physiological function may be impaired, thus gaining traction for prevention of EP.
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ABSTRACT 
Introduction: Formaldehyde (FA) is a common, volatile organic compound used in organic 
preservation with known health effects of eye, nose, and throat irritation linked to oxidative stress and 
inflammation. Indeed, long-term FA exposure may provoke skin disorders, cancer, and cardiovascular 
disease. However, the effects of short-term FA exposure on the vasculature have yet to be investigated. 
Purpose: We sought to investigate the impact of an acute FA exposure on: 1) macrovascular function 
in the arm (brachial artery flow-mediated dilation, FMD), 2) microvascular function in the arm (brachial 
artery reactive hyperemia, RH) and leg (common femoral artery, supine passive limb movement, PLM), 
and 3) circulating markers of oxidative stress (xanthine oxidase, XO; protein carbonyl, PC; and 
malondialdehyde, MDA) and inflammation (C-reactive protein, CRP). Methods: Ten (n=10) healthy 
females (23±1y) were studied before and immediately after a 90-minute FA exposure ([FA]: 
197±79ppb) in cadaver dissection laboratories. Results: Brachial artery FMD% decreased following 
FA exposure (Pre-FA Exp: 9.41±4.21%, Post-FA Exp: 6.74±2.57%, p=0.043), and FMD/Shear 
decreased following FA exposure (Pre-FA Exp: 0.13±0.07AU, Post-FA Exp: 0.07±0.03AU, p=0.016). 
The area under the curve for brachial artery RH (Pre-FA Exp: 481±191ml, Post-FA Exp: 499±165ml) 
and common femoral artery PLM (Pre-FA Exp: 139±95ml, Post-FA Exp: 129±64ml) were unchanged 
by FA exposure (p>0.05). Circulating MDA increased (Pre-FA Exp: 4.8±1.3µM, Post-FA Exp: 
6.3±2.2µM, p=0.047) while XO, PC, and CRP were unchanged by FA exposure (p>0.05). Conclusion: 
These initial data suggest a short FA exposure can adversely alter vascular function and oxidative stress, 
influencing cardiovascular health. 
Word Count: 245  
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NEW AND NOTEWORTHY 
This study was the first to investigate the implications of acute formaldehyde (FA) exposure on adult 
female vascular function in the arms and legs. The main findings from this study were a decrease in 
conduit vessel function without any alteration to microvascular function following a 90-minute FA 
exposure. Additionally, the oxidative stress marker malondialdehyde increased after FA exposure. 
Taken together, these results suggest acute FA exposure have deleterious implications for the 
vasculature and redox balance.  
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INTRODUCTION 
 Formaldehyde (FA) is volatile organic compound (VOC) which readily reacts with organic 
material (1). As a Group 1 carcinogen, the Centers for Disease Control describes FA as capable of 
disrupting proteins, making FA an exceptional bactericide and fungicide (2). Such uses of FA include 
organic material preservation, most notably in the timber industry (3), healthcare professions (4), and 
even in cadaver preservation common in medical education (5, 6), making it one of the most common 
and hazardous air pollutants (7). Exposure to FA can occur directly to the skin, yet FA typically is 
unintentionally inhaled, causing irritation (8) and potential cellular damage to the epithelial lining of 
conducting airways (9). Further, FA can readily cross the pulmonary alveolar membrane (10, 11) and 
elicit deleterious effects in the circulation, leading to cardiovascular pathologies and disease risk 
production (12) similar to other airborne pollutants (13). 
 Most evidence suggesting FA exposure can lead to cardiovascular impairments stems from cell 
culture and animal models. Human umbilical vein cell (HUVEC) studies suggest endothelial cells are 
particularly vulnerable to FA exposure and result in cellular damage (14, 15).  Low- and high-level FA 
exposures in rat aortas both in vivo and in vitro exhibited a paradoxical vasoconstriction and 
vasodilation response, respectively (16), suggesting FA may have a direct, concentration-dependent 
effect on vascular function. Observations of oxidative stress and likely macrophage-induced 
inflammation in the rat lung following FA exposure (17, 18) suggest a peripheral effect of 
cardiovascular impairments could be secondary to an airborne exposure to FA. Collectively, these data 
provide evidence for FA to elicit numerous direct and indirect effects on vascular function, yet little is 
known regarding the ability of FA to induce vascular alterations in humans. 
Among human epidemiological data, growing evidence has linked FA exposure to an increase 
in systemic oxidative stress. Several occupational industries including nursing (4), pathology wards (5), 
cosmetic industry (19), plastic lamination (9), and wood industry (3) have provided evidence for 
heightened oxidative stress among FA exposed workers. Airborne pollutant-induced increases in 
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oxidative stress have the ability to decrease nitric oxide (NO) bioavailability, resulting in worsened 
endothelial-dependent vasoreactivity (20) which may increase the risk of cardiovascular events (21, 
22). While this has not been tested with FA exposure, we speculate that FA-induced increase in 
oxidative stress may act similarly as other airborne pollutants to induce endothelial and vascular 
dysfunction. Indeed, investigations into the potential effects of FA exposure on the human vasculature 
are critically needed to examine a potential link between FA exposure and vascular health. 
Therefore, this study sought to assess the impact of acute FA exposure on vascular function 
using clinically relevant and well-established vascular assessments: brachial artery flow-mediated 
dilation (FMD) (21-23) and reactive hyperemia (RH) (24, 25) in the arm and passive limb movement 
(PLM) (26, 27) in the leg. Using a natural experimental approach, we hypothesized that acute FA 
exposure, such as that typically experienced in anatomy cadaver dissection laboratories, would decrease 
FMD, RH and PLM, thus providing evidence for the ability of FA to impact vascular function. 
Furthermore, circulating markers of oxidative stress (xanthine oxidase, XO; protein carbonyl, PC; and 
melanodialdehyde, MDA) and an inflammatory marker predictive of cardiovascular disease (C-reactive 
protein, CRP) (28) were determined as potential mechanisms of vascular dysfunction, which we 
hypothesized would increase in response to acute FA exposure. While sex-specific consequences of air 
pollution are contentious, analyses of respiratory modifications report a stronger effect of various air 
pollutants among females than males, regardless of menstrual phase (29). Likewise, exposure to 
pollution of fine particulates may have a larger impact on female life expectancy (30). These sex-
specific decrements in health following airborne pollutant exposure may be associated with systemic 
oxidative stress and inflammation along with subsequent vascular dysfunction (31) and arterial stiffness 
(32). Hence, this initial study sought to focus on the effects of acute FA exposure among female adults.  
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METHODS         
Study Population. 
Ten female adults, who were beginning cadaver dissection courses wherein they would be 
exposed to FA, were recruited for this investigation from Appalachian State University and Elon 
University. Subjects were tested within the first two weeks of the laboratory start date to ensure minimal 
previous exposure to FA. The subjects received a single FA exposure 2 to 5 days prior to study 
participation as a familiarization to the laboratory setting but were otherwise naïve to the longer, 90-
minute FA exposure in which they were in close proximity to FA sources. Exclusion criteria included 
any known cardiovascular disease, amenorrhea, current or past smokers who were regularly exposed 
to high amounts of VOCs in cigarette smoke (33), hormone replacement therapy other than oral 
contraceptive use, chronic antioxidant/anti-inflammatory use, or individuals who were pregnant or 
trying to become pregnant. All procedures were approved by Appalachian State University and Elon 
University Institutional Review Boards, and measurements were performed in a thermoneutral 
environment. The subjects provided informed consent in accordance with the standards outlined by the 
Declaration of Helsinki. 
 
Study Procedures. 
Subjects were tested in the morning in a fasted state, having abstained from caffeine, alcohol, 
and exercise for 24 hours prior to a 90-minute FA exposure. Testing occurred in a quiet, thermoneutral 
environment (692-736 mmHg barometric pressure, 22-23o C temperature, 33-50% relative humidity). 
All procedures were performed with subjects lying supine for 20 minutes prior to testing. Data 
collection included FMD, RH, PLM, and a venous blood draw. Subjects were then instrumented with 
a chest-mounted FA sensor prior to entering the cadaver dissection laboratory for 90-minutes where 
they were actively dissecting cadavers which were embalmed with a 37% FA solution. During the time 
in the cadaver dissection laboratory, subjects actively took part in cadaver dissection activities, standing 
over the FA preserved human donors which remained on stainless-steel cadaver tables at waist height. 
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Within the laboratories, subjects wore nitrile or latex gloves and garments to cover arms and legs to 
further prevent FA exposure directly to the skin, although masks were not worn. Following FA 
exposure, subjects left the cadaver laboratory and proceeded to the testing room where they were 
reassessed 29 ± 11 minutes after the 90-minute FA exposure. Study procedures were ordered similarly 
prior to and following FA exposure to maintain standardization. 
 
Formaldehyde Sensors. Subjects wore FA sensors (FM-801 Formaldehyde meter, Graywolf Sensing 
Solutions, LTD, Annacotty, Ireland) anteriorly on a chest harness in an effort to measure individual FA 
exposure levels, due to personal exposure levels often being higher than ambient room FA 
concentrations, especially during cadaver dissections when FA is more readily emitted from cadavers 
to close proximity individuals (34, 35). The FA sensors use photoelectric photometry with accurate 
readings to 10 ppb. Airborne FA levels were measured using photoelectric photometry (407-424nm) as 
30-minute averages for continuous data-monitoring. Sensors were calibrated for >60 minutes prior to 
FA exposure in the testing room according to manufacturer’s instructions. FA levels were also recorded 
in the testing room where FMD, RH, PLM, and blood draw measurements were conducted before and 
after subject FA exposures in the cadaver dissection laboratory which were in the same building as the 
FA exposure to minimize distance traveled between repeated measurements. 
 Each anatomy laboratory was assessed for FA exposure levels within the past year using FA 
passive monitoring badges (Sensor Safety Products, Raleigh, NC). The Appalachian State University 
anatomy laboratory was built 1 year prior to this study taking place, is 95 square meters, and has 
downdraft cadaver dissection tables with in-table ventilation to draw air down under the cadavers and 
out of the room and building through a ventilation system with 100% fresh air turn over 12.5 times per 
hour. The Elon University School of Health Sciences anatomy laboratory was built 9 years prior to this 
study taking place, is 201 square meters, and has a ventilation system with 100% fresh air turn over 13 
times per hour. Appalachian State University anatomy laboratory was tested within 4 months of this 
study taking place with FA levels below the acceptable OSHA permissible exposure limits of 750 ppb 
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for an 8-hour time-weighted average, and did not exceed the NIOSH Recommended Exposure Limit 
of 16 ppb for a 10-hour time-weighted average. Elon University School of Health Sciences anatomy 
laboratory was tested within 7 months of this study taking place with FA levels below the acceptable 
OSHA permissible exposure limits of 750 ppb for an 8-hour time-weighted average, but exceeded the 
NIOSH Recommended Exposure Limit of 16 ppb for a 10-hour time-weighted average. These results 
are consistent with low level exposure in an anatomy laboratory setting.  
 
Experimental Measurements. 
Brachial artery FMD and RH. Brachial artery FMD and RH measurements were obtained from the 
right brachial artery using current guidelines (36). Baseline measurements of the right brachial artery 
diameter and blood velocity were taken for 1 minute using a Doppler ultrasound system (GE Logiq eR7 
and L4-12T-RS transducer, GE Medical Systems, Milwaukee, WI). Sample volume was optimized in 
relation to vessel diameter and centered within the vessel for each subject. Measurements of brachial 
artery diameter and velocity were obtained with the Doppler ultrasound in duplex mode with B-mode 
imaging frequency of 12 MHz and Doppler frequency of 4 MHz. An angle of insonation of ≤60° (37) 
was achieved for all measurements. Immediately after baseline measurements, a blood pressure cuff, 
placed distal to the elbow, was rapidly inflated to 250 mmHg for 5 minutes. The blood pressure cuff 
was rapidly deflated, and brachial artery diameter and velocity were recorded for 2 minutes. Brachial 
artery diameter, blood velocity, blood flow, shear rate, and RH were analyzed offline for continuous 
second-by-second measurements (Cardiovascular Suite version 4.0, Quipu, Pisa, Italy). Blood flow was 
determined as: 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 𝐹𝐹𝐵𝐵𝐵𝐵𝐹𝐹 =  [π (arterial diameter / 2)2] · blood velocity, where blood velocity 
was obtained as the time average mean on the Doppler ultrasound. 
 
Passive Leg Movement. Following brachial artery FMD procedures, resting, supine brachial artery 
blood pressures [systolic blood pressure, SBP; diastolic blood pressure, DBP; pulse pressure, PP, as the 
15





∗ 𝑆𝑆𝐵𝐵𝑀𝑀�] and heart rate were obtained to determine resting central hemodynamics and to calculate 
vascular conductance as blood flow relative to MAP. Following these measurements of supine central 
hemodynamics, supine PLM was performed using current guidelines (26). While in the supine position 
with the subject’s left leg supported on a stool and right leg supported by a research team member at 
heart level, baseline measurements of the common femoral artery diameter and blood velocity, at least 
3 cm proximal the femoral artery bifurcation, were recorded for 1 minute prior to passive limb 
movement using similar Doppler ultrasound system settings used for the brachial artery FMD 
procedure. Immediately following baseline measurements, the research team member supporting the 
right thigh and ankle manually moved the knee joint one time through 90⁰ range of motion, flexion-
extension, at 1 Hz while common femoral artery diameter and blood velocity were recorded for one 
minute after the movement. Following this single passive limb movement (sPLM), measurements were 
repeated as the research team member manually moved the knee joint through 90⁰ range of motion, 
flexion-extension, at 1 Hz continuously for one minute while common femoral artery diameter and 
blood velocity were recorded for one minute during this continuous passive limb movement (cPLM). 
Similar to the brachial artery FMD analyses, femoral artery diameter, blood velocity, and blood flow 
were analyzed offline for continuous second-by-second measurements (Cardiovascular Suite version 
4.0, Quipu, Pisa, Italy). Resting, supine brachial mean arterial blood pressure (MAP) was used to 
normalize blood pressure as vascular conductance. The peak change in blood flow (ΔPeakBF) and 
vascular conductance (ΔPeakVC) along with the 60-second area under the curve (AUC 60s) were 
determined as indices of microvascular function (26).  
 
Blood Draw. Blood draws were performed by a certified phlebotomist following vascular 
measurements. Plasma were separated by centrifugation and stored at -80 oC until analysis. 
Biochemical assays were performed according to manufacturer's instructions in duplicate for the 
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oxidative stress biomarkers XO using a fluorometric assay (Cayman Chemical, Ann Arbor, MI, 
#10010895), PC using a colorimetric assay (Cayman Chemical, Ann Arbor, MI, #10005020), and MDA 
using a colorimetric assay (Cayman Chemical, Ann Arbor, MI, #10009055) as well as the inflammatory 
biomarker CRP using an enzyme-linked immunosorbent assay (Cayman Chemical, Ann Arbor, MI, 
#10011236). 
 
Statistical Analysis. Statistics were performed using commercially available software (IBM SPSS 
Statistics version 26, Armonk, NY, USA). Paired two-tailed student’s t-tests were performed, and data 
were checked for normality using Shapiro Wilk's Test and boxplots. Effect sizes are reported using 
Cohen’s dav. Statistical significance was specified at p < 0.05. Subject characteristics and variables of 
interest are expressed as mean ± SD. As an exploratory Post Hoc analysis, Pearson correlations were 
performed for the association between significant markers of vascular dysfunction and biomarkers of 
oxidative stress and inflammation.   
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RESULTS 
Subject Characteristics. Subject characteristics of all ten subjects are presented in Table 1. One of the 
females who underwent FMD and RH testing did not undergo PLM or blood draw measurements.  
 
FA Exposure. The average FA exposure among 9 subjects who wore the FA sensors during the 90-
minute FA exposure was 197 ± 79 ppb, with 30-minute average FA levels ranging from 20 to 356 ppb. 
The lowest 30-minute FA exposure averaged 152 ± 78 ppm. The highest 30-minute FA exposure 
averaged 247 ± 90 ppb. Among the 30-minute average FA levels, 5 of the 9 measured subjects exceeded 
an FA exposure of 250 ppb during the 90-minute FA exposure time period. FA concentrations in the 
testing room were below 10 ppb which was the lowest detectable level among the five separate FA 
sensors utilized at any given time. 
 
Brachial Artery FMD. Measurements of brachial artery FMD are presented in Figure 1 and Table 2. 
Baseline diameter did not change due to FA exposure (p = 0.318, Cohen’s dav = 0.38). There was a 
tendency for the peak diameter to decrease following FA exposure (p = 0.054, Cohen’s dav = 0.70). 
However, the absolute change in diameter was not different following FA exposure (p = 0.371, Cohen’s 
dav = 0.49). The time to peak diameter did not change due to FA exposure (p = 0.515, Cohen’s dav = 
0.35). The sum of shear experienced at peak diameter increased following FA exposure (p = 0.0.35, 
Cohen’s dav = 0.82) (Table 2). The peak change in diameter expressed as a percent, FMD% (Pre-FA 
Exp: 9.41 ± 4.21 %, Post-FA Exp: 6.74 ± 2.57 %, p = 0.043, Cohen’s dav = 0.79) and FMD normalized 
to the shear rate (Pre-FA Exp: 0.13 ± 0.07 AU, Post-FA Exp: 0.07 ± 0.03 AU, p = 0.016, Cohen’s dav 
= 1.20) decreased following FA exposure (Figure 1A and Figure 1B, respectively). 
 
Brachial Artery Reactive Hyperemia. Blood flow measurements from before and after cuff occlusion 
are shown in Figure 2. Brachial artery blood flow prior to cuff occlusion was unchanged by FA 
exposure (Pre-FA Exp: 86.4 ± 18.5 ml∙min-1, Post-FA Exp: 97.5 ± 60 ml∙min-1, p = 0.536, Cohen’s dav 
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= 0.53). Likewise, the blood flow response to the 5-minute cuff occlusion, as assessed by AUC, was 
unchanged by FA exposure (Pre-FA Exp: 481 ± 191 ml, Post-FA Exp: 499 ± 165 ml, p = 0.831, Cohen’s 
dav = 0.10). 
 
Supine Central Hemodynamics. Nine out of the ten subjects underwent supine testing for central 
hemodynamics in preparation for PLM testing. Blood pressure and heart rate measurements from before 
and after FA exposure are shown in Table 3. Resting supine SBP, DBP, PP, MAP, and HR were 
unchanged by FA exposure (p > 0.05). 
 
Passive Leg Movement. Nine out of the ten subjects underwent PLM testing prior to and following FA 
exposure. Measurements of sPLM are presented in Table 4 and Figure 3. Common femoral artery 
blood flow or vascular conductance at baseline did not change due to FA exposure (p > 0.05) (Table 
4). Peak blood flow, peak vascular conductance, the change in blood flow from baseline to peak, and 
the change in vascular conductance from baseline to peak were not altered by FA exposure (p > 0.05) 
(Table 4). The blood flow response to the sPLM, as assessed by AUC 60s (Pre-FA Exp: 139 ± 95 ml, 
Post-FA Exp: 129 ± 64 ml, p = 0.824, Cohen’s dav = 0.13) and vascular conductance response to the 
sPLM, as assessed by AUC 60s (Pre-FA Exp: 1.91 ± 1.28 ml∙mmHg-1, Post-FA Exp: 1.41 ± 0.74 
ml∙mmHg-1, p = 0.376, Cohen’s dav = 0.50) were unchanged by FA exposure (Figure 3).  
 Measurements of cPLM are presented in Table 4 and Figure 4. Common femoral artery blood 
flow and vascular conductance at baseline did not change due to FA exposure (p > 0.05) (Table 4). 
Peak blood flow, peak vascular conductance, the change in blood flow from baseline to peak, and the 
change in vascular conductance from baseline to peak were not altered by FA exposure (p > 0.05) 
(Table 4). The blood flow response to the cPLM, as assessed by AUC 60s (Pre-FA Exp: 391 ± 220 ml, 
Post-FA Exp: 309 ± 195 ml, p = 0.171, Cohen’s dav = 0.40) and vascular conductance response to the 
cPLM, as assessed by AUC 60s (Pre-FA Exp: 4.54 ± 2.22 ml∙mmHg-1, Post-FA Exp: 3.37 ± 2.2 
ml∙mmHg-1, p = 0.162, Cohen’s dav = 0.53) were unchanged by FA exposure (Figure 3). 
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Circulating levels of inflammation and oxidative stress. Nine out of the ten subjects had blood drawn 
prior to and following FA exposure. Measurements of circulating levels of oxidative stress and 
inflammation are presented in Table 5. Oxidative stress makers XO and PC did not change following 
FA exposure (p > 0.05). However, MDA increased following FA exposure (p < 0.05). The 
inflammatory marker CRP did not change following FA exposure (p > 0.05). The mean intra-assay 
coefficient of variation for all analyzed biomarkers revealed good reproducibility across duplicate 
samples (XO: 11.0%, PC: 4.3%, MDA: 7.1%, and CRP: 4.1%). The Pearson correlation between the 
change in FMD% from Pre-FA to Post-FA with the change in MDA from Pre-FA to Post-FA was not 





This study sought to identify the potential impact of an acute FA exposure on vascular function 
in the arms and legs of adult females, as well as the potential alterations to circulating levels of oxidative 
stress and inflammatory biomarkers. Our hypothesis was partially correct that FMD, as a percent 
change and when normalized to shear, decreased following a 90-minute FA exposure, suggesting 
vascular function in the brachial artery conduit vessel was impaired. However, as indicated by a lack 
of change to brachial artery RH, downstream vascular function in the small arterioles and 
microcirculation were not altered by the acute FA insult. Additionally, the lack of change to the 
common femoral artery blood flow response to either the sPLM or cPLM further corroborates the 
notion that the vasculature downstream of the conduit vessels were unaffected by the FA exposure. 
Despite a lack of change in microvascular function, we observed conflicting results in our circulating 
markers of oxidative stress without observable increases in either XO or PC but an increase in MDA. 
Furthermore, there was no change to the inflammatory marker CRP. This investigation represents some 
of the first data to identify a decrease vascular function in adult females following an acute FA exposure 
which may be attributable, at least in part, to an increase in oxidative stress. 
 
Brachial Artery FMD with FA Exposure. The brachial artery FMD technique is a non-invasive, 
endothelial-dependent assessment of systemic vascular function (23) which strongly correlates with 
coronary vascular function (21) and is predictive of future cardiovascular events (22).  Results from 
HUVEC studies suggest FA exposure can damage endothelial cells (15), which may directly initiate 
plaque formation, oxidative stress, and vascular disorders (14). Additional investigations in isolated 
aortic rings of rats have revealed a potential role of endothelin-induced vasoconstriction in response to 
low FA incubation (<300 μM), while higher levels of FA incubation (>500 μM) may decrease NO 
bioavailability (16). These studies highlight the potential impact of FA exposure to endothelial cells 
and the vasculature, while also stressing the importance of translational investigations in human 
vascular health. In the current investigation, the 3% decrease in brachial artery FMD is clinically 
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meaningful, as every 1% decrease in brachial artery FMD% is associated with a ~13% increased risk 
of cardiovascular events such as heart attack, stroke, or death (38). These observations, representing 
the first data to address the potential contribution of FA exposure to alter upper extremity vascular 
function in humans, suggest a rapid decrement in vascular function following a relatively short bout of 
FA exposure which have ramifications for cardiovascular health, even among young healthy 
individuals. Future research should certainly discern whether these decrements are shared among other 
populations, most notably individuals at higher risk for cardiovascular disease who may ultimately 
show a greater FA-induced decrement or among those with an already compromised vasculature, such 
as individuals with hypertension or heart failure. Furthermore, dose, duration, and repeated exposures 
of FA are needed to further understand the potential impact of FA to vascular function. 
 
Brachial Artery Reactive Hyperemia with FA Exposure. Whereas brachial artery FMD provides an 
assessment of vascular function in the conduit artery, brachial artery RH provides an index of 
microvascular function which is inversely related to cardiovascular disease risk (24) and is predictive 
of future cardiovascular events in healthy and diseased populations (25). The lack of change in brachial 
artery RH in the current investigation (Figure 2) alludes to a lack of dysfunction among the small 
arterioles or microvasculature shortly after an acute FA exposure. Microvascular assessment of 
exposure to VOCs such as cigarette smoke are contentious. While some cross-sectional analyses of 
cigarette smokers compared to non-smokers have failed to show a change in brachial artery RH (39), 
acute exposure to VOCs in cigarette smoke have resulted in a decrease in brachial artery RH (40). One 
potential explanation for the discrepancy between our observed brachial artery vasodilatory 
impairments and lack of microvascular impairments with acute FA exposure may reside in the 
vasodilatory mechanisms contributing to each assessment. While brachial artery FMD is arguably a 
functional bioassay for endothelial-derived NO (41-43), the reactive hyperemic response to forearm 
cuff occlusion is only minimally influenced by NO (44, 45) and rather alternative pathways such as 
inwardly rectifying K+ channels and Na+/K+ ATPase (46). If FA-induced oxidative stress is reducing 
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NO bioavailability and subsequent brachial artery FMD, perhaps the acute insult of oxidative stress 
observed in the current investigation is sparing microvascular dysfunction, albeit during this acute time 
period following FA exposure. Further, if oxidative stress has a delayed induction of inflammation 
which has been observed in animal models of FA exposure (17, 18), inflammation as a secondary insult 
may lag behind the increase in oxidative stress and lead to additional microvascular impairments hours 
to days following an acute FA exposure. Certainly, more work is warranted to discern if higher 
concentrations or durations of FA exposure may impose additional decrements downstream in the 
vascular tree and if prolonged effects following FA exposure may influence microvascular function. 
   
Passive Limb Movement. The PLM maneuver has emerged as lower limb assessment of microvascular 
function (26) which may be attributable to a number of central and peripheral factors (27). While the 
sPLM elicits a minimal central hemodynamic response, the cPLM is thought to incorporate 
mechanoreflex type III/IV afferent feedback (47), thus providing sufficient time to increase cardiac 
output as an integrative response to the cPLM maneuver (48). This study represents the first 
investigation to address the potential contribution of FA exposure to alter lower limb vascular function, 
as assessed by the PLM maneuver. In the present investigation, a lack of change was observed in either 
the sPLM or cPLM maneuver when comparing the effect of FA exposure on either blood flow or 
vascular conductance (Table 4). Together, the sPLM and cPLM maneuvers provide insight into lower 
limb vascular function which corroborate our findings from the brachial artery RH in the arm, as both 
techniques assess microvascular function. Combined, these data suggest the acute effect of FA exposure 
on the vasculature may have regional rather than global distinctions among the vascular tree.  
 
Oxidative Stress and Inflammation with FA Exposure. Oxidative stress is a primary mechanism by 
which airborne pollutants are thought to inflict global health decrements (49). The axis of oxidative 
stress, inflammation, and vascular function has been well recognized, as a feedback loop of oxidative 
stress and inflammation which produce free radicals, diminish antioxidant capacity, uncouple eNOS 
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from superoxide anions, reduce NO bioavailability, and ultimately impair vascular function (50). 
However, many uncertainties exist regarding the interplay of redox balance and vascular function, 
especially among FA exposure. 
Oxidative stress plays a central role in the response to acute airborne pollutants. Studies from 
smokers (51) and bus drivers (52) exposed to VOCs provide evidence for increased circulating levels 
of the primary superoxide generator XO as well as protein oxidation biomarker PC, respectively. 
However, investigations on the effect of human exposure to FA on XO and PC are lacking. As observed 
in the current investigation (Table 5), XO and PC were unaffected by an acute exposure to FA. These 
results suggest elevations in XO and PC are not mutually exclusive to all VOCs and may not follow 
similar patterns, albeit acutely, after exposure to FA. Further investigations may wish to investigate the 
effects of repeated bouts of FA exposure on these oxidative stress markers. 
 Epidemiological investigations also suggest increases in oxidative stress following FA 
exposure, especially among lipid oxidation. Nurses (4) and wood industry workers (3) exposed to FA 
experienced an increase in the lipid oxidation biomarker 15-F2t-isoprostane. Plastic laminate plant 
workers who are regularly exposed to FA had elevated levels of M1dG adducts, a biomarker of 
oxidative stress and lipid peroxidation (9). Similar to smokers regularly exposed to VOCs (51), 
exposure to FA yielded an increase in the global lipid peroxidation biomarker MDA among nurses (4), 
pathology ward workers (5), and cosmetic industry workers (19). The current investigation observed 
an increase in MDA (Table 5) with acute exposure to FA, which suggests the potential for FA to rapidly 
increase lipid oxidation. Yet, this change in MDA was not associated with a change in vascular function. 
Future studies should certainly discern if a time course effect exists among these biomarkers and 
whether oxidative stress persists hours to days following initial FA exposure. 
While important to consider the effects of oxidative stress on vascular function, the balance of 
antioxidant defenses combating reactive oxygen species should be considered when further evaluating 
the potential impact of FA exposure on the vasculature. Concentrations of the antioxidant glutathione, 
which can oxidize FA to formic acid (53), can decrease in response to a 4-week FA exposure in rats 
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(54), suggesting antioxidants may be expendable to prevent a rise in reactive oxygen species. Several 
investigations using animal models provide evidence for antioxidant administration, such as rose oil 
(55), lavender oil (56), or melatonin (56) to improve redox balance and have protective effects against 
FA-induced cellular damage. Further investigations should certainly discern between the ability of 
endogenous or exogenously administered antioxidants to modulate oxidative stress and whether 
antioxidant levels diminish due to acute, chronic, and repeated FA exposures which may have further 
implications for cardiovascular health.  
In addition to oxidative stress, FA can induce an inflammatory response. Studies in rats have 
identified an increase in leukotriene B4, thromboxane B2, interleukin-1, interleukin-6 and vascular 
endothelial growth factor which may play a role in the inflammatory response to FA exposure (17, 18). 
Additionally, administration of the antioxidants vitamins C, E, and apocynin in rats was able to prevent 
this rise in FA-induced inflammation (18), suggesting a role of oxidative stress in generating lung 
inflammation which may also be present systemically. Furthermore, CRP is a sensitive marker of 
inflammation, tissue damage, and infection (57) which is an independent risk factor for cardiovascular 
disease events (28, 58). Long-term exposure to VOCs in cigarette smoke increases CRP among smokers 
which may be reversable with years of smoking cessation (59). This suggests CRP may be influenced 
by other VOCs such as FA. Despite this evidence for enhanced inflammatory responses to FA and other 
VOCs, the current investigation failed to detect a change in CRP following an acute FA exposure for 
90 minutes (Table 5). Over a long enough time period, oxidative stress may exacerbate inflammation 
and reduce vascular function (50). Yet, more work is needed to investigate the effects of higher FA 
concentrations, repeated exposures, and long-lasting consequences which may enhance inflammatory 
pathways for hours to days following an FA exposure and may contribute to additional decrements in 
vascular function.  
 
Limitations. We recognize the nature of this natural experimental design may have had several 
confounding variables. Mental stress may enhance cortisol levels which are negatively associated with 
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vasodilation during the traditional FMD technique, and these heightened cortisol levels can be 
ameliorated with administration of the antioxidant Vitamin C (60), suggesting an association between 
oxidative stress, autonomic outflow, and vascular function. Likewise, the enhanced sympathetic 
nervous system response to the cold pressor test (61) may influence the traditional FMD (62) as well 
as sustained, exercise-induced increase in shear rate (63). Further, mental stress caused by decreased 
sleep quality has been well documented as influencing vascular function through alterations in vascular 
resistance and conduit artery shear stress profiles (64-66). While stress cannot be ruled out as a 
confounding variable in the current investigation, the lack of change in supine central hemodynamics 
in response to FA exposure (Table 3) may suggest a lack alteration to autonomic outflow which may 
otherwise influence vascular function in the current study. Future investigations may wish to control 
for such forms of mental stress, especially when assessing repeated days of FA exposure commonly 
experienced in occupational settings. Further, the females studied in the current investigation had 
variations in contraceptive use and menstrual cycle fluctuations which may contribute to variable 
responses to airborne pollutants, as the cardio-protective attributes of estrogen should not be overlooked 
(67, 68). However, previous accounts of endothelial function were not altered across the menstrual 
cycle and with oral contraceptive use (69) which suggests the current findings may not be confounded 
by the menstrual cycle. While it is enticing to monitor plasma FA levels, FA has a half-time of only 1-
1.5 minutes in plasma (70), making monitoring FA metabolites, such as formate salts in the urine, the 
next best option (19), despite levels of detection of formate being questionable during relatively low 
levels of FA exposure (71). Additionally, as standing may be beneficial over prolonged sitting for 
micro- and macrovascular function (72-74), the effect of FA exposure on the vasculature among 
individuals who were standing over cadavers for 90-minutes may have been more pronounced had the 
subjects been sitting. Certainly, more work is needed to identify if postural or light physical activity 
may influence these vascular alterations. Given the acute nature of the current investigation, additional 
time points after FA exposure are needed to identify any time course effect in future investigations. 
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Perspectives. Many occupations encounter FA on a daily basis including those in the lumber and 
cosmetic industries, as well as those in healthcare professions, the latter of which often encounter high 
FA levels in their cadaver-based anatomy dissection training. While modern cadaver laboratories utilize 
exhaust systems within, above, or near cadaver tables, the FA exposure levels may remain 2-3 times 
higher than average indoor FA levels and may exceed OSHA and NIOSH guidelines (6, 34). In the 
current investigation, the use of personal FA monitors was essential to identify a ~20-fold variation in 
30-minute average FA exposure levels among individuals who were in the same working environment 
while performing the similar tasks. In practice, the level of FA exposure to those who are instructing, 
learning, and working is of great theoretical importance and should not be assumed to be equal within 
similar working environments. Indeed, more work is needed to investigate repeated and duration-
dependent effects of FA exposure on the vasculature which many individuals may be exposed to for 
several hours over the course of years, possibly having additive effects on cardiovascular disease risk. 
Furthermore, future work may wish to investigate the potential acute or chronic interventions to 
ameliorate these effects of FA exposure on vascular function, especially among those who are regularly 
exposed to this common occupational hazard. 
 
Conclusion. To the best of our knowledge, this is the first study to identify the potential effects of an 
acute FA exposure on peripheral vascular function in female adults, which may have ramifications for 
cardiovascular health. A relatively short, 90-minute FA exposure, which was within OSHA 
recommended FA exposure concentration limits (75), was sufficient to diminish brachial artery FMD 
and increase oxidative stress immediately after FA exposure among healthy female adults. While 
further research is surely necessary to identify additional impacts of various FA exposure 
concentrations and durations among both sexes, aging individuals, and those who are more susceptible 
to cardiovascular disease, these data provide guidance for the cautionary use of FA within indoor 
environments.   
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Figure 1. Brachial artery flow-mediated dilation. Brachial artery flow-mediated dilation (FMD) 
expressed as percent change (A; p = 0.043, Cohen’s dav = 0.79) and normalized to shear (B; p = 0.016, 
Cohen’s dav = 1.20) before formaldehyde exposure (Pre-FA Exp) and after (Post-FA Exp). Individual 
trends shown in grey bars, n=10. Paired two-tailed student’s t-tests were performed between Pre-FA 
and Post-FA Exp. * p<0.05. Data are Mean ± SD. 
 
Figure 2. Brachial artery reactive hyperemic response to cuff occlusion. Brachial artery reactive 
hyperemic response to cuff occlusion expressed as absolute blood flow response before formaldehyde 
exposure (Pre-FA Exp) and after (Post-FA Exp). Inset depicts area under the curve for the 120 seconds 
after cuff occlusion (AUC 120s) with individual trends shown in grey bars, n=10, p = 0.831, Cohen’s 
dav = 0.10. Paired two-tailed student’s t-tests were performed between Pre-FA and Post-FA Exp. Data 
are Mean ± SD. 
 
Figure 3. Single passive limb movement. Common femoral artery blood flow response to a single 
passive limb movement (A; p = 0.824, Cohen’s dav = 0.13) before formaldehyde exposure (Pre-FA Exp) 
and after (Post-FA Exp). Vascular conductance response to a single passive limb movement (B; p = 
0.376, Cohen’s dav = 0.50). Insets depict area under the curve for the 60 seconds after sPLM (AUC 60s) 
with individual trends shown in grey bars, n=9. Paired two-tailed student’s t-tests were performed 
between Pre-FA and Post-FA Exp AUC. Data are Mean ± SD. 
 
Figure 4. Continuous passive limb movement. Common femoral artery blood flow response to 
continuous passive limb movements (A; p = 0.171, Cohen’s dav = 0.40) before formaldehyde exposure 
(Pre-FA Exp) and after (Post-FA Exp). Vascular conductance response to continuous passive limb 
movements (B; p = 0.162, Cohen’s dav = 0.53). Insets depict area under the curve for the 60 seconds 
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during cPLM (AUC 60s) with individual trends shown in grey bars, n=9. Paired two-tailed student’s t-
tests were performed between Pre-FA and Post-FA Exp AUC. Data are Mean ± SD. 
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Table 1. Subject characteristics. 
Subject Characteristics 95% CI 
Subjects, n 10 












3.4 ± 1.1 
44 ± 14 
2.7, 4.1 
35, 53 
Contraceptive Use, n 8 
CI, confidence interval. Data are Mean ± SD. 
36
Table 2. Flow-mediated dilation. 




95% CI Effect Size 
p-
value 
Baseline diameter, mm 3.36 ± 0.44 3.09, 3.63 3.21 ± 0.34 3.00, 3.42 -0.14 ± 0.43
-0.41,
0.13 0.38 0.318 
Peak diameter, mm 3.72 ± 0.46 3.44, 4.00 3.47 ± 0.25 3.32, 3.63 -0.25 ± 0.36 
-0.47, -
0.03 0.70 0.058 
Change in diameter, mm 0.36 ± 0.28 0.19, 0.53 0.26 ± 0.13 0.18, 0.34 -0.10 ± 0.34
-0.31,
0.11 0.49 0.371 
Time to peak diameter, sec 56 ± 21 43, 69 64 ± 25 49, 80 8 ± 37 -15, 31 0.35 0.515 
Sum of shear at peak, AU 8.2 ± 3.1 6.3, 10.1 10.7 ± 3.0* 8.8, 12.6 2.5 ± 3.2 0.5, 4.5 0.82 0.035 
n = 10. Paired two-tailed student’s t-tests were performed along with Cohen’s dav effect size. AU, arbitrary units; CI, confidence interval. * p<0.05. 
Data are Mean ± SD.  
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Table 3. Supine central hemodynamics. 
 Pre-FA 










Systolic blood pressure, mmHg 106 ± 8 101, 111 108 ± 4 105, 111 2 ± 8 -3, 7 0.33 0.591 
Diastolic blood pressure, mmHg 76 ± 4 73, 79 77 ± 4 74, 80 1 ± 4 -2, 4 0.25 0.546 
Pulse pressure, mmHg 30 ± 5 27, 33 31 ± 4 28, 34 1 ± 6 -3, 5 0.22 0.761 
Mean arterial pressure, mmHg 89 ± 5 86, 92 91 ± 4 88, 94 2 ± 6 -2, 6 0.46 0.439 
Heart rate, bpm 70 ± 12 62, 78 74 ± 11 67, 81 3 ± 12 -5, 11 0.35 0.411 
n = 9. Paired two-tailed student’s t-tests were performed along with Cohen’s dav effect size. BF, blood flow; CI, confidence interval. Data are Mean 
± SD.  
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Table 4. Passive limb movement. 








Baseline BF, ml/min 522 ± 208 386, 658 470 ± 206 335, 605 -53 ± 145 -148, 42 0.25 0.304 
Peak BF, ml/min 968 ± 251 804, 1130 874 ± 316 
668, 
1080 -93 ± 181 -211, 25 0.33 0.160 
ΔPeakBF, ml/min 445 ± 117 369, 521 404 ± 169 294, 514 -40 ± 202 -172, 92 0.29 0.565 
Baseline VC, ml/min/mmHg 5.8 ± 2.3 4.3, 7.3 5.0 ± 2.0 3.7, 6.3 -0.8 ± 1.5 -1.8, 0.2 0.37 0.159 
Peak VC, ml/min/mmHg 10.7 ± 2.7 8.9, 12.5 9.4 ± 3.4 7.2, 11.6 -1.3 ± 1.8 -2.5, -0.1 0.43 0.061 
ΔPeakVC, ml/min/mmHg 4.9 ± 1.3 4.1, 5.8 4.4 ± 2.0 3.1, 5.7 -0.5 ± 2.3 -2.0, 1.0 0.31 0.492 
Continuous PLM 
Baseline BF, ml/min 513 ± 176 398, 628 547 ± 214 407, 687 35 ± 134 -53, 123 0.17 0.462 
Peak BF, ml/min 1246 ± 324 1030, 1460 1200 ± 312 
996, 
1400 -45 ± 188 -168, 78 0.14 0.489 
ΔPeakBF, ml/min 733 ± 252 568, 898 653 ± 214 513, 793 -80 ± 160 -185, 25 0.34 0.173 
Baseline VC, ml/min/mmHg 5.7 ± 1.8 4.5, 6.9 5.9 ± 2.2 4.5, 7.3 0.2 ± 1.5 -0.8, 1.2 0.10 0.683 
Peak VC, ml/min/mmHg 13.8 ± 3.4 11.6, 16.0 13.0 ± 3.5 
10.7, 
15.3 -0.8 ± 2.1 -2.2, 0.6 0.23 0.298 
ΔPeakVC, ml/min/mmHg 8.1 ± 2.7 3.6, 9.9 7.1 ± 2.5 5.5, 8.7 -1.0 ± 1.8 -2.2, 0.2 0.38 0.136 
n = 9. Paired two-tailed student’s t-tests were performed along with Cohen’s dav effect size. BF, blood flow; CI, confidence interval; VC, vascular 
conductance. Data are Mean ± SD. 
39
Table 5. Circulating levels of oxidative stress and inflammation. 
 




95% CI Effect Size 
p-
value 
Oxidative Stress               
Xanthine oxidase, 
µU/ml 15.2 ± 24.6 -0.9, 31.3 20.6 ± 36.8 -3.4, 44.6 5.4 ± 25.3 -11.1, 21.9 0.18 0.540 
Protein carbonyl, 
pmol/ml 7.3 ± 5.2 3.9, 10.7 6.0 ± 6.4 1.8, 10.2 -1.3 ± 5.5 -4.9, 2.9 0.22 0.493 
Malondialdehyde, 
µM 4.8 ± 1.3 4.0, 5.7 6.3 ± 2.2 * 4.9, 7.7 1.5 ± 1.9 0.3, 2.7 0.86 0.047 
Inflammation               
C-reactive 
protein, pg/mol 1684 ± 1232 879, 2490 1989 ± 1335 1120, 2860 304 ± 803 -221, 829 0.24 0.288 
n=9. Paired two-tailed student’s t-tests were performed along with Cohen’s dav effect size. CI, confidence interval.  * p<0.05. Data are Mean ± SD.  
40
Figure 1. Brachial artery flow-mediated dilation. 
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ABSTRACT 
Background: Formaldehyde (FA) is commonly utilized preservation agent contained within many 
household and industrial products, as well as in the solutions common to medical laboratories and 
mortuaries. Yet, FA is also a known carcinogen and pulmonary irritant.  
Purpose: To investigate the effects of FA exposure during a cadaver dissection laboratory on pulmonary 
function and biomarkers of inflammation. 
Methods: Students from two regional universities were recruited to perform pulmonary function testing 
and provided blood samples before and after following a 90-min cadaver dissection laboratory session. 
Spirometry was measured by having subjects complete forced vital capacity (FVC) and maximal voluntary 
ventilation (MVV) maneuvers following American Thoracic Society guidelines. The NHANES III dataset 
was used to calculate percent predicted values. Pre- and post-FA exposure data were subsequently 
compared.  
Results: Before entering the laboratory, subjects (N=17; two males; 24±3yr; 24±4kg∙m-2) displayed normal 
pulmonary function, as indicated by the percent predicted values for FVC (97±10%), forced expiratory 
volume in one second (FEV1; 96±11%), and MVV (102±16%). Subjects were exposed to 192 ± 124 ppb of 
FA over the course of the dissection period. Following the session, no changes were observed for any of 
the spirometric parameters examined (FVC, 0±3%Δ; FEV1, 0±4%Δ; MVV, 0±0%Δ). Further, there were 
no correlations between the percent changes in FVC or FEV1 and FA exposure concentrations as well as 
inflammatory biomarkers (r2<0.06).  
Conclusion: Acute exposure to FA over the course of a single dissection laboratory does not impair 
pulmonary function. 





 Formaldehyde (FA) is a chemical commonly used during the production of many industrial and 
household products such as resins, paint, textiles, glues, cosmetics, paper products, particle board, etc. 
Additionally, FA-containing solutions are used within medical laboratories and mortuaries to preserve 
cadavers 1 due to its strong bactericidal, fungicidal, and insecticidal properties 2. While the Occupational 
Health and Safety Administration (OSHA) has set permissible exposure limits for short- (15 min; 2 ppm) 
and long-term (8 hr; 0.75 ppm) exposures 3, many workers, as well as students enrolled in human cadaver 
dissection laboratories as part of their clinical education, may be exposed to levels of FA under the 
recommended limits but that still have been demonstrated to be sensitive to the eyes, nasal cavity, pharynx, 
and/or respiratory tract.  
  It is clear that chronic exposure to FA results in respiratory dysfunction 4-6 and is associated with 
greater risks of certain types of cancer7 and overall mortality8. Additionally, repeated FA exposure in the 
workplace has been linked to decrements in pulmonary function in workers 4,9; notable changes to forced 
vital capacity (FVC) and the forced expiratory volume in one second (FEV1) have been documented 
following five years of chronic, high exposure10. Yet, the degree, if any, to which cardiorespiratory health 
is affected following acute FA exposure is less clear, especially when exposed to acceptable concentrations 
as determined by OSHA. Further, students involved in cadaver dissections within a gross anatomy course 
or actively engaged in medical laboratory activities may be exposed to levels of FA that impair normal 
respiratory function 11-13. In contrast, a meta-analysis concluded that the potential changes to common 
spirometry measures were not physiologically meaningful 14. The equivocal findings among investigations 
may be attributed to differences in the FA inhalation dosage (i.e., exposure concentrations, durations, and 
pulmonary ventilations) in subjects between each study, as well as between subjects within the same study. 
For example, depending on the level of involvement in the dissection activities, it is possible for two 
individuals within the same medical laboratory to be exposed to vastly different FA concentrations, and 
individual exposures likely will be greater than the mean room concentration 15. Thus, if the individual 
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exposures are not accounted for or are completely unknown, interpretation of findings regarding respiratory 
function following FA exposure can be difficult at best or inaccurate at worst. 
 Studies have shown that FA exposures are commonly associated symptoms of respiratory distress 
(e.g. wheezing, productive cough, runny nose, headache) 13,14,16-18. The immediate irritation to tissue mucosa 
is likely attributed to the high solubility of FA in water where it can deposit and be metabolized within 
neighboring cells. Yet, the exact mechanisms by which FA exposure can illicit changes to pulmonary 
function have not been fully delineated. It was recently demonstrated that FA modulates Ca2+ pathways in 
airway smooth muscle cells, which can result in airway narrowing 19. Additionally, exposure to 
formaldehyde may lead to eosinophilia and greater cytokine release, leading to an inflammatory response 
that could contribute to bronchoconstriction 20. Further, it has been hypothesized that disruption of the 
pathways involved in the relaxation of airway smooth muscle cells resulting in bronchodilation also may 
be altered 21. Indeed, FA exposure has been linked to the development of symptoms characteristic of asthma 
in animal models 22,23, as well as to an increased risk of developing asthma in children and adults 24,25. 
Furthermore, individuals with asthma may to be particularly susceptible to the respiratory consequences of 
acute FA exposure due to the already-heightened immune response 26. Since we recently demonstrated that 
vascular dysfunction results from a single FA exposure bout, even when the FA exposure is within OSHA 
limits, and that the observed dysfunction corresponded with increased indicators of oxidative stress 27, we 
believe pulmonary function has the potential to be altered in conjunction with increased cytokine 
appearance in the blood.  
The purpose of this study was to measure pulmonary function and circulating markers of 
inflammation in the before and after acute exposure to FA. A secondary purpose was to examine the 
relationships between the changes in pulmonary function parameters, circulating markers of inflammation, 
and individual FA concentration levels. We hypothesized that pulmonary function would be impaired, as 
evidenced by reductions in FVC and FEV1, following a single acute exposure to FA within a medical 
laboratory. Additionally, we believed biomarkers of inflammation would be elevated as a result of the FA 
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exposure. Furthermore, we hypothesized that the degree of pulmonary function impairment, change in 






 Individuals enrolled in a cadaver dissection laboratory course at one of two regional universities 
were recruited for participation. Subjects were studied during the first two weeks of the cadaver dissection 
course to minimize previous exposure to FA; the subjects received a single FA exposure 2 to 5 days prior 
to study participation as a familiarization to the laboratory setting but were otherwise naïve to the longer, 
90-minute FA exposure.  All subjects were at least 18 years of age. Exclusion criteria included any known 
cardiovascular or metabolic disease, current or past smokers, or individuals who were pregnant or trying to 
become pregnant. All procedures were approved by Appalachian State University and Elon University 
Institutional Review Boards. The subjects provided informed consent in accordance with the standards 
outlined by the Declaration of Helsinki.  
Study Design 
Following informed consent, all subjects completed a health history questionnaire. Subsequently, 
subjects completed pulmonary function testing (n = 17) and provided a blood sample (n = 12) before a 90-
min cadaver dissection laboratory period (Pre). A subset of the subjects (n = 11) were randomly selected to 
wear FA sensors mounted to chest harnesses. During the time in the cadaver dissection laboratory, subjects 
actively took part in cadaver dissection activities, standing over the FA-preserved human donors, which 
remained on stainless-steel cadaver tables at waist height. During the dissection activities, subjects wore 
nitrile or latex gloves and garments to prevent FA contact with the skin. Subjects did not wear masks during 
the dissection period. Following the FA exposure period, subjects left the medical laboratory and proceeded 
to the physiological testing room where pulmonary function was reassessed and another blood sample was 
collected (Post). 
Formaldehyde Concentrations 
Subjects wore FA sensors (FM-801 Formaldehyde meter, Graywolf Sensing Solutions, LTD, 
Shelton, CT) anteriorly on a chest harness in an effort to measure individual FA exposure levels, since 
individual exposure levels are often higher than ambient room FA concentrations, especially during cadaver 
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dissection activities 15. The sensors determined airborne FA levels using photoelectric photometry (407-
424nm). Sensors were calibrated for >60 minutes prior to the FA exposure period. Subjects entered in the 
cadaver dissection laboratory where they remained for 90 min. Ambient air was continuously monitored 
for FA, and 30 min averages were reported. FA concentrations also were recorded in the physiological 
testing environment before and after the FA exposure period. The physiological testing environments and 
medical laboratories were located within the same buildings on each campus, which minimized the time 
and activity between the exposure period and reassessment. 
Pulmonary Function Testing 
 Pulmonary function testing was performed according to American Thoracic Society 
recommendations using a portable, handheld spirometer (EasyOne Plus, ndd Medical Technologies, 
Andover, MA). Subjects were asked to perform a minimum of three FVC maneuvers. With a nose clip 
secured, subjects inspired to total lung capacity and were encouraged to forcefully expire to residual 
volume. Two maneuvers were required to meet the criteria of repeatability as defined by two FVC 
measurements within 0.150 L. The largest values for each of FVC and FEV1 were selected for future 
comparisons. Additional parameters were selected from the single best maneuver (equal to the sum of FVC 
and FEV1) and included peak expiratory flow (PEF), forced expiratory flows (FEF) over the midexpiratory 
range (25, 50, and 75% FVC), and the forced expiratory time (FET 100%). Following completion of the 
FVC maneuvers, subjects were asked to perform a maximum voluntary ventilation (MVV) test for 12 s, 
and measured volumes were multiplied by five to extrapolate the 12-s volume to a minute value. 
Participants were coached and encouraged throughout the MVV test. The largest value of two repeatable 
trials (<10% difference) was used for statistical comparison. Environmental conditions within each 
physiological testing environment were consistent over the course of the study period (Site 1: 730.1 ± 6.4 
mmHg, 22.8 ± 0.5° C, 40 ± 8 %; Site 2: 692.0 ± 0.0 mmHg, 21.5 ± 0.5° C, 34 ± 1 %). All data are reported 
as absolute values (corrected to body temperature, pressure, saturated conditions) and as percentages of 
predicted (%pred) using the National Health and Nutrition Examination Survey (NHANESIII) data set28. 
Inflammatory Biomarkers 
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 Blood samples were collected by a certified phlebotomist following pulmonary function testing. 
Plasma were separated by centrifugation and stored at -80°C until analysis. Interleukin-6 (IL-6; Cayman 
Chemical, Ann Arbor, MI; no.501030) and 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE; Cayman 
Chemical, Ann Arbor, MI; no.534721) were analyzed in triplicate using the enzyme-linked immunosorbent 
assay technique according to manufacturer’s instructions. The coefficient of variation was < 10% (2.6 ± 2.1 
%) for all samples. The mean concentrations of the triplicate samples were used in subsequent statistical 
comparisons.  
Statistical Analysis 
 Statistical comparisons of pulmonary function and inflammatory biomarker measurements before 
and after FA exposure were completed using paired samples t tests (IBM, Armonk, NY). Pearson’s 
correlations were calculated to assess the relationships between pulmonary function, blood biomarker, and 
FA concentrations. For all tests, statistical significance was set at p < 0.05. Descriptive data are reported as 






 Subject characteristics are reported in Table 1. Two male subjects participated, and their data are 
displayed separately for informative purposes only. Three of the subjects reported being diagnosed with 
asthma as children and were included in the study without assessment of airway reversibility. 
Formaldehyde Concentrations 
 FA concentration over the full 90-min exposure period was 192 ± 124 ppb (minimum = 16 ppb; 
maximum = 352 ppb) for all subjects. However, 30-min averages ranged from as low as 10 ppb to as high 
as 473 ppb. Seven subjects were exposed to concentrations of at least 250 ppb during a single 30-min period. 
Individual readings are reported in Table 2. 
Pulmonary Function Testing 
 FVC was maintained from before to after the 90-min FA exposure period (Pre: 3.93 ± 0.79 L, Post:  
3.92 ± 0.86 L; p > 0.05).  Measurements of FVC were 97 ± 10 %pred and 97 ± 9 %pred at the Pre and Post, 
respectively, physiological assessment time points. FEV1 was 96 ± 11 %pred before and 96 ± 11 %pred 
after the FA exposure period. Thus, FEV1 was unchanged as a result of the exposure to FA (Pre: 3.33 ± 
0.66 L, Post:  3.33 ± 0.68 L; p > 0.05).  Additional pulmonary function measurements are reported in Table 
3. Like the observations of FVC and FEV1, significant changes were not observed for forced expiratory 
flows over the midexpiratory range from before to after the 90-min FA exposure period. There were no 
significant correlations between the percent changes from before to after the FA exposure in FVC, FEV1, 
FEV1/FVC, FEF25-75%, and MVV and the 90-min average formaldehyde exposure concentrations (all p > 
0.05; Figure 1). 
Inflammatory Biomarkers 
 Circulating levels of IL-6 within the blood were unchanged from before to after the FA exposure 
period (Pre: 2.51 ± 6.27 pg∙mL-1, Post:  2.65 ± 6.32 pg∙mL-1; p > 0.05). Additionally, 15(S)-HETE did not 
change as a result of the FA exposure (Pre: 2547 ± 633 pg∙mL-1, Post: 2331 ± 728 pg∙mL-1; p > 0.05). No 
statistically significant relationships were observed between changes in the circulating concentrations of 
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IL-6 and 15(S)-HETE and any changes in pulmonary function measures including %ΔFVC (IL-6: p = 
0.827; 15(s)-HETE: p = 0.787), %Δ FEV1 (IL-6: p = 0.925; 15(s)-HETE: p = 0.067), %Δ PEF (IL-6: p = 
0.591; 15(s)-HETE: p = 0.105), and %Δ FEF25-75% (IL-6: p = 0.537; 15(s)-HETE: p = 0.250) or the FA 





  Measures of spirometry are not found to significantly change, nor are the percent changes of 
individuals correlated with formaldehyde concentrations during a 90-min exposure. Finally, circulating 
markers of inflammation were not found to change with a 90-min FA exposure, nor were they correlated 
with percent changes of spirometry. 
 
Formaldehyde Exposure 
Both laboratories included in the current study were well within the standards set by OSHA (Table 
2) (ref 3). Large differences in exposure can be attributed to area of dissection with higher concentrations 
being the abdominal cavity and lower concentrations dissection of the back and head11. While the 
concentrations of FA did not exceed the OSHA guidelines, large variability is shown in our measurements 
of FA concentration in the air which would agree with studies that examined individual exposure levels to 
concentrations of the room 15,29. 
 
Pulmonary Function 
There were no detriments to pulmonary function associated with acute exposure to FA30. Attention 
was drawn to variables associated with effort of the participant as a non-maximal maneuver could skew the 
data. Observation of percent predicted values confirm high performance across variables (>80 % predicted), 
thus are indicative of maximal effort. The lack of difference could be explained by duration of FA exposure 
not being great enough to elicit a decrement to bronchial function for a decrease in FEV1; however, the 
assumption of decreased bronchial function is not likely as Schachter and coauthors found that airway 
resistance was not altered in response to FA 31 . As previously stated, FA is readily dissolved in the upper 
respiratory tract resulting in a required increase ventilation or FA concentration to elicit the bronchial 
decrement associated with decreased FEV1 32. The non-significant pre to post exposure FVC values are 
within reason of the current literature. In a study by Harving et al. 33, asthmatic non-smoking persons were 
subjected to FA exposure at differing dosages in which no change in FEV1 was seen. Similar studies have 
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attempted to determine the acute effects of FA on both asthmatics and non-asthmatic persons, to which 
many find that there are no decrements in pulmonary function 31,34. 
  For pulmonary function changes to occur, lung tissue would have to undergo massive remodeling 
35-37. Remodeling of significance would likely take week to months of exposure before pulmonary function 
saw a true decrement 38. An animal study which used approximately 22.5 ppm 1 hr/day, 5 days/week for 
two weeks saw significant increases in total cells of the bronchoalveolar lavage which could be attributed 
to the huge amount of formaldehyde showing that large amounts of formaldehyde would be required for an 
acute exposure to expose significance in formaldehyde exposure 39. 
Furthermore, histamine thresholds did not change in asthmatics pre to post exposure confirming 
that the perceived irritation may not be associated with inflammatory markers, or at least the ones tested 
for 33. A longitudinal study of medical students found that a month after baseline, there was a significant 
decrease in FVC and FEV1 to which the authors suspect that the FA dissolved in the upper respiratory tract 
elicit an immune response40. Animal studies have found an increased inflammatory response based on FA 
concentration as it relates to the bronchoalveolar lavage fluid and oxidative stress 23,41,42. 
 
Inflammatory Biomarkers 
IL-6 is a cytokine associated with inflammation. It has been shown that increased levels of IL-6 are 
related to reduced FVC as well as reduced FEV1 43,44. Additionally, it has been found that the amount of IL-
6 is related to the concentration of pollution 45. Due to the inflammation associated with FA exposure as 
well as the route of exposure via vapors, we hypothesize that IL-6 would be increased as a function of 
pulmonary function. While our subjects were exposed to FA for 90 minutes, it is possible that this is not a 
sufficient time to invoke an inflammatory response given that an ischemic stimulus was only party visible 
on immunopositivity scales between 4-6 hr following stimuli where as widespread expression was observed 
following 6-8 hr in cell cultures46. 
15(S)-HETE was chosen as a biomarker inflammation as it has shown, in cell culture, the largest increase 
in the presence of arachidonic acid47. 15(S)-HETE is a metabolite of arachidonic acid, via 15-lipoxygenase, 
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and a member of a class of biochemical known as eicosanoids. Epithelial cells are often the first to observe 
the consequences of irritable substances, such as FA, given the highest concentration will be incurred.  
While 15-HETE is one of many eicosanoids associated with the lungs, it has particular implications as cell 
cultures of epithelial cells have demonstrated the largest production of 15-HETE compared to other 
metabolites of the lipoxygenase pathway47. Indeed, high production of a biochemical is not always 
causative, some eicosanoids are known to cause constriction of pulmonary smooth muscle 48 as well as 
stimulate airway mucus secretion49. Due to the known irritations and inflammation associated with FA 
exposure, we hypothesize that 15(S)-HETE will increase in response to an acute FA exposure.  
 
Conclusion 
There are no differences between pre to post-acute exposure pulmonary function in young 
otherwise healthy adults. Furthermore, the percent change of FVC and FEV1 pre to post were not correlated 
with the average concentration of FA inspired during laboratory cadaver dissection. While this study’s 
findings are similar to other research, it is still unclear as to how studies have found decrements in 
pulmonary function following acute exposure. Potential improvement of the findings could be found if 
assessment of subjective symptoms were recorded via survey as seen in some of the previous literature 
5,14,16,17,50. Further research should be completed to assess whether percent changes in pulmonary function 
are associated with average FA exposure as this could explain occupational hazards. 
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Male 2 28 ± 6 183 ± 3 84 ± 3 25 ± 2 
Female 15 23 ± 2 164 ± 6 65 ± 15 24 ± 4 
Combined 17 24 ± 3 166 ± 8 66 ± 15 24 ± 4 




Table 2. Formaldehyde concentration (ppb) 
30 min 60 min 90 min 
196 231 271 
253 356 225 
125 113 117 
130 232 231 
238 248 321 
320 316 232 
193 473 389 
238 329 362 
11 29 16 
10 29 10 
36 33 44 









Table 3. Pulmonary Function 
Measurement   Pre   Post   p value 
FEV1/FVC, %  85.10 ± 6.58  85.40 ± 5.83  0.719 
FEF25-75%  3.81 ± 1.09  3.86 ± 1.05  0.791 
 %pred  100 ± 25  101 ± 27  0.755 
FEF25%, L∙s-1  6.35 ± 1.61  6.43 ± 1.74  0.802 
FEF50%, L∙s-1  4.50 ± 1.38  4.79 ± 1.50  0.239 
FEF75%, L∙s-1  2.00 ± 0.70  1.87 ± 0.47  0.283 
PEF, L∙s-1  7.62 ± 1.78  7.74 ± 1.90  0.638 
 %pred  102 ± 13  104 ± 17  0.664 
FET 100%  5.54 ± 1.53  5.32 ± 1.53  0.409 
MVV, L∙min-1  122 ± 27  125 ± 33  0.424 
 %pred  102 ± 16  103 ± 19  0.428 
𝑓𝑓B, 
breaths∙min-1  103 ± 15  105.67 ± 18  0.471 
VT, 
L     1.23 ± 0.34   1.22 ± 0.30   0.751 
Values are expressed as mean ± SD. All variables that have reference values 
in the Third National Health and Nutrition Examination Survey have been 
reported beneath as % predicted, respectively. FVC, forced vital capacity; 
FEV1, forced expiratory volume in 1 s; FEF, forced expiratory flow; PEF, 
peak expiratory flow; FET, forced expiratory time; MVV, maximal voluntary 
ventilation; 𝑓𝑓B, frequency of breathing; VT, tidal volume. * Significantly 




Figure 1: The percent change in an individual’s force vital capacity (FVC, A), forced expiratory volume 
in 1 s (FEV1,B), FEV1/FVC (C), midexpiratory flow of middle 50% of FVC (FEF25-75%, D), peak 
expiratory force (PEF, E), and maximal voluntary ventilation (MVV,F) were not correlated with 








Electronic Cigarettes (EC) are a popular alternative to tobacco smoking that has taken hold 
since the early 2000s. This fact could be due to the reduced number of chemicals as well as reduced 
concentrations of EC vapor compared with tobacco smoke (44) which did include formaldehyde. 
Given the novelty of the EC, questions have been synthesized to assess the safety of EC use as it 
compares to tobacco smoking. Acutely, it has been shown that lung function is maintained with no 
differences between placebo, tobacco and EC trials (45). Given that pulmonary function is 
maintained, it is interesting that the increasing concentration of nicotine significantly decreases the 
expired NO thus leading to increased airway resistance (46), though this has been observed in studies 
not focused on the concentration of particles or nicotine (47). 
Contrary to the, relatively, maintained lung function of acute EC usage, seldom are humans 
stationary. Therefore, studies have attempted to assess aerobic function of persons that use EC which 
has found that in vitro, EC vapor elevate mitochondrial reactive oxygen species (48).  
Speculations on exercise responses to acute EC usage might be made by observing articles 
that measure traditional cigarettes. For instance, it was observed that increased carbon monoxide was 
bound to hemoglobin when smoking compared with nonsmoking and ultimately resulted in a reduced 
V̇O2max (49). However, as previously stated, the use of EC is increasing and the normal activity of 
people should be objective data while using these products given the link of tobacco smoking to 
chronic, life-changing pathologies. 
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ABSTRACT 
BACKGROUND: Increased airway resistance has been shown in electronic cigarette users which has 
important implications to cardiorespiratory function during exercise, where large expiratory air flow rates 
are required to meet the ventilatory and metabolic demands. 
PURPOSE: To investigate the acute effects of EC use on exercise tolerance and exertional dyspnea in 
young adults. 
METHODS: Male participants (N=10; 21±2yr, 180.4±8.1cm, 84.9±13.3kg) visited the laboratory on five 
occasions. Subjects completed pulmonary function testing for familiarization (FAM) purposes during the 
initial visit. During the subsequent two visits, subjects inhaled from an EC with (EC+) or without (EC-; 
i.e., placebo) the nicotine cartridge in random order. Two additional visits performed the EC smoking
challenge followed by an incremental exercise test to volitional exhaustion on a cycle ergometer. 
RESULTS: Upon study entry, all subjects displayed pulmonary function measurements above the lower 
limits of normal. Airway resistance increased comparing FAM with EC- and EC+, though no differences 
between EC- and EC+ were observed. Maximal oxygen consumption was not different between trials (p > 
0.05). Ventilation, operational lung volumes, and the ventilatory equivalents for O2 and CO2 were only 
different by intensity and did not change due to the EC challenge. Heart rate was not different between 
conditions; however, oxygen pulse was lower in the EC+ (p=0.043). 
CONCLUSION: These data suggest that individuals may experience differences to airway function and 
oxygen pulse suggesting unperceivable alterations at rest and during exercise. Potentially, exercise 
stimulus is sufficient to overcome or override the alterations to airway resistance. 




Electronic cigarettes (EC) are devices intended to deliver an aerosol by rapidly heating an inhaled solution 
containing nicotine and possible flavorings and/or additives. They are marketed as a method for quitting 
tobacco smoking, as a healthier alternative to tobacco smoking, and as a method to “smoke” in public 
spaces. Many teenagers and young adults, however, are increasingly using the unregulated devices due the 
belief that EC are less harmful than tobacco cigarettes 1 and/or the appeal of candy and fruit flavors. As of 
2018 estimates suggest that as many as 25.8% of US adults aged 18-24 have used an EC and nearly 8% of 
whom are current users2. While there is much ongoing debate about their benefits and efficacy as a tobacco 
cessation aid 3-5, little is known about the immediate health consequences posed by their use.  
Assessments of respiratory function with EC use have been conducted to elucidate its potential effects on 
measurements of air flow, volume, and gas exchange6-8. Six months of daily EC usage has been associated 
with decrements to forced expiratory volume in 1 s (FEV1), the ratio of FEV1 to forced vital capacity (FVC) 
and forced expiratory flow in the middle 50% of FVC (FEF25-75%)9. Additionally, chronic EC users have 
been found to exhibit a greater degree of ventilation-perfusion mismatch when compared with non-EC users 
10. In contrast, in naïve subjects, pulmonary function does not appear to be altered with acute EC use, as 
FEV1, FVC, and FEF25-75% are conserved 6-8. Yet, it is recognized airway function can be impaired prior to 
observing significant changes in common pulmonary function measurements. Impulse oscillometry, a more 
sensitive technique to examine airway function, has demonstrated that EC usage increases airway resistance 
despite not affecting spirometry measurements 6,7 Furthermore, the fraction of expired nitric oxide (FENO), 
an indicator of bronchial function, is altered following acute EC usage 6,11. These findings suggest that 
airway function is impaired, even when no decrements to common indicators of spirometry are observed, 
and that over time, gas exchange abnormalities may result in chronic users. These potential perturbations 
may be exaggerated and alter ventilatory responses during exercise when high levels of airflow and 
ventilation are required.   
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The link between cardiovascular health and tobacco cigarette usage is indisputable. Tobacco smokers are 
at greater risk of developing cardiovascular diseases, including hypertension, peripheral artery disease, and 
myocardial infarction. Yet, it is unclear to what extent acute and chronic EC usage affects cardiovascular 
function. Recently, it was demonstrated that EC usage increased heart rate (HR), pulse wave velocity, and 
augmentation index corrected to 75 heart beats per minute measured at rest which are indicative of potential 
future events given a trend to tachycardia as well as stiffening of the vessels7,12,13. These potential risk 
factors are not maintained when myocardial function was observed in chronic EC users suggesting that 
while vascular health is at risk, myocardial function could be preserved14.. Given that high temperature 
vaporization of the EC liquid has shown to produce formaldehyde, decrements to cardiovascular function 
may result from the formaldehyde exposure as our group has shown arterial stiffening with acute exposure 
to formaldehyde in addition to decrements to flow-mediated dilation and increased heart rate15,16. The 
potential for formaldehyde to be the cause of cardiovascular detriments associated with EC is not conserved 
across all studies as flow-mediated dilation has also shown to be preserved when comparing EC users, 
tobacco cigarette users, and naïve subjects17. 
The potential physiologic consequences to acute EC usage have important implications to the respiratory 
and cardiovascular function exhibited during exercise, where large expiratory air flow rates and increased 
blood flow to active tissues are required to meet the ventilatory and metabolic demands. Furthermore, in 
the face of mechanical constraints to ventilation during exercise, which can occur with increased airway 
resistance, breathing may be forced to occur at higher lung volumes closer to total lung capacity where 
maximal expiratory flows are greater 18. However, this shift in the operational lung volume occurs where 
the mechanical work and metabolic cost of breathing are greater. Subsequently, the perception of dyspnea 
during exercise may be elevated as a result of the increased respiratory muscle effort required to achieve 
the necessary exercise ventilation and may serve as a limitation to exercise performance 19. Yet, it is 
unknown whether… Thus, the purpose of this study was to investigate the acute effects of EC use on 
cardiorespiratory function and exertional dyspnea during incremental exercise in young adults. We 
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hypothesized that cardiorespiratory function would be altered, and exertional dyspnea increased in young 
adults following EC use. 
Methods 
Subject Characteristics 
Ten (N=10) male subjects participated in the current investigation. Subjects were otherwise healthy and 
free of any known metabolic, cardiovascular, and respiratory disease. Additionally, five subjects reported 
cessation from smoking and history of less than 2 pack years and no longer habitually smoking. Subjects 
were not currently aerobically training as reported by an International Physical Activity Questionnaire 
(IPAQ). All subjects gave written informed consent to protocols approved by the Institutional Review 
Board of Appalachian State University. The study was performed in accordance with the ethical standards 
as described in the Declaration of Helsinki. 
 
Protocol 
Subjects visited the laboratory on five occasions, each separated by a minimum of 48 h, to complete all 
testing procedures. Following completion of informed consent and medical history questionnaires, subjects 
completed a pulmonary function familiarization test (FAM). Subsequently, subjects were familiarized to 
the EC smoking task. During visits two and three, subjects performed the EC smoking task with (EC+) and 
without (EC-; i.e., placebo) the nicotine cartridge in random order before completing pulmonary function 
testing. Similarly, during visits four and five, subjects performed the EC smoking task with (EC+) and 
without (EC-; i.e., placebo) the nicotine cartridge in random order before completing an incremental 




EC Smoking Task 
A commercially available EC was chosen without bias (blu™ Magnificent Menthol). The nicotine content 
of the menthol flavored cartridge was 2.4% (24 mg/mL) accompanied with glycerin vehicle (75%). The 
product was a classic EC (first generation) with a rechargeable cartomizer. This particular device has been 
shown to elicit the largest on plasma nicotine when compared with other EC of similar styles 20. Subjects 
inspired from an adapter connected to the EC every 30 s for 10 min for a total of 20 inspirations from the 
EC. The adapter contained a side port for the measurement of mouth pressure. Subjects were instructed to 
generate an inspiratory mouth pressure (Pi) of -20 cmH2O for 2 s, as this was meant to simulate typical 
behavior when smoking11. Subjects received continuous visual feedback displayed on a computer monitor 
regarding the achieved and target mouth pressures (DASYLab, Norton, MA). All expired air was collected 
into an opaque Douglas bag connected to a one-way valve. The EC smoking task was designed in an effort 
to blind subjects to the nicotine containing cartridge. 
Pulmonary Function 
Spirometry and lung volumes were measured according to American Thoracic Society guidelines21. 
Measurements of spirometry were conducted in a volume-displacement plethysmograph (Vmax, 
CareFusion, Yorba Linda, CA) to account for gas compression artifact. Subjects were asked to maximally 
expire following a full inspiration. The occluded panting technique was used to measure functional residual 
capacity (FRC), which was followed by an inspiratory capacity and complete expiratory maneuvers to 
measure total lung capacity (TLC) and residual volume (RV), respectively. Airway resistance was measured 
using the changes in flow and mouth pressures during a panting maneuver with an open shutter. Triplicate 
measurements of spirometry (FVC <150 mL), lung volumes (FRC ≤ 5%), and airway resistance were 
measured. Volumes were corrected to body temperature, pressure, and saturated conditions. Absolute 
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values are reported as well as percent of predicted (%pred) using the third National Health and Nutrition 
Examination Survey (NHANES III) prediction equations22. 
 
Incremental Exercise Test 
An exercise test was performed on an upright electromagnetically braked cycle ergometer (Lode Corival, 
Netherlands). Subjects were instrumented with a forehead pulse oximeter (Nellcor N-595, Minneapolis, 
MN) and a heart rate strap (Polar Electro, Kempele, Finland). Metabolic gases were analyzed using a 
metabolic cart (Parvo Medics, Salt-Lake City, Utah). 
Subjects remained seated on the cycle ergometer for six minutes for the collection of resting measurements. 
Two inspiratory capacity (IC) maneuvers were completed during the last minute of rest to correct for 
expiratory drift for analysis of breathing mechanics. Following the IC maneuvers, subjects began cycling 
at 30 W using a cadence of 60-80 rpm. The cycling work rate increased by 30 W every minute until 
volitional exhaustion. During each minute of exercise, subjects completed an IC maneuver and were asked 
to provide ratings of perceived breathlessness (RPB; Borg scale 0-10), perceived unpleasantness of 
breathing (RPU; Borg scale 0-10), and perceived exertion (RPE; Borg scale 6-20). Following completion 
of exercise, subjects were asked to rate their affective dimensions of dyspnea (unpleasantness, anxiety, 
depression, anger, frustration, and fear) on a visual analog scale (VAS) pertaining to their highest achieved 
RPB during exercise23. 
 
Flow, volume, and pressure 
Air flow was measured using pneumotachographs (Model 4813, Hans Rudolph, Kansas City, MO) on both 
the inspiratory and expiratory sides of a low resistance two-way valve (model 2700, Hans Rudolph, Kansas 
City, MO). The pneumotachograph located on the expiratory side was heated to minimize condensation. 
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Inspiratory and expiratory air flows were integrated to yield volumes. Pressures were measured at the mouth 
(Pm) via calibrated pressure transducer (+30 cmH2O; DP45, Vaildyne, Northridge, CA). All raw data were 
continuously collected using Spike 2 software (Cambridge Electrical Design, United Kingdom) on a 
Micro1401 32-bit AD converter (Cambridge Electrical Design, United Kingdom). Mouth pressures were 
integrated by time and multiplied by breathing frequency to achieve an index of inspiratory and expiratory 
work of breathing (WoB) as outlined by Collett, 198524. 
 
Operational lung volumes 
Approximately 8-12 breaths were analyzed during each stage to examine operational lung volumes. End-
expiratory lung volumes (EELV) were calculated as TLC minus IC. Tidal volume (VT) was added to EELV 
to calculate the end-inspiratory volumes (EILV). Expiratory flow limitation (EFL) was calculated by 
overlaying the exercise tidal flow-volume loop with the compression-free maximal flow-volume loop 
(mFVL) obtained during spirometry. The percentage of EFL was calculated as: 
EFL % = �
volume overlap
VT
� ∗ 100 
 
Statistical Analysis 
Analysis of findings were assessed using commercially available software (IBM SPSS Statistics Version 
27, Armonk, NY). A repeated measure analysis of variance (ANOVA) was used to compare parameters 
measured during the EC smoking task across the four intervention trials. Additionally, a repeated measures 
ANOVA was performed to examine the potential difference in pulmonary function between FAM, EC-, 
and EC+. Two-way repeated measures ANOVA (condition by stage) were performed to assess 
cardiorespiratory responses throughout exercise during EC- and EC+. Violations of Mauchly’s Test of 
Sphericity were accommodated using the Huynh-Feldt correction. Post hoc analyses using a least 
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significant difference (LSD) were performed where family-wise significance was detected. Statistical 
significance was set at p ≤ 0.05. Data are expressed as mean ± standard deviation (SD). Partial eta squared 




Subject characteristics are displayed in Table 1.  
 
EC Smoking Task 
Subject’s peak Pm was not different between conditions for the EC smoking task (EC-: -20.34 ± 3.95 
cmH2O; EC+: -21.30 ± 2.21 cmH2O; p = 0.380, η2p = 0.111). Additionally, a one second moving average 
of Pm was not different between conditions for the EC smoking task (EC-: -19.95 ± 3.94 cmH2O; EC+: -
20.95 ± 1.85 cmH2O; p = 0.390, η2p = 0.107). The integrated Pm was not different between EC smoking 
tasks (EC-: -25.56 ± 8.32 cmH2O∙s; EC+: -28.24 ± 5.01 cmH2O∙s; p = 0.295, η2p = 0.155). 
 
Pulmonary Function 
With the exception of FEV1 expressed as a percent of predicted, spirometry and lung volume 
measurements were similar between FAM, EC-, and EC+ trials (Table 2). MVV was not different 
between the three trials (99 ± 10 %pred, 101 ± 10 %pred, 101 ± 8 %pred, respectively; p > 0.05). 
Measurements of airway resistance (Raw: 1.75 ±0.65 cmH2O∙s∙L-1, 2.05 ± 0.62 cmH2O∙s∙L-1, and 1.98 ± 
0.53 cmH2O∙s∙L-1; p = 0.039, η2p = 0.303) were significantly greater following the EC smoking task than 
during FAM. Yet, airway conductance (Gaw: 0.63 ± 0.20 L∙cmH2O-1∙s-1, 0.53 ± 0.12 L∙cmH2O-1∙s-1, 0.54 
± 0.11 L∙cmH2O-1∙s-1; p = 0.079, η2p = 0.290) was not different between trials. Raw and Gaw were not 
different between EC- and EC+ (p > 0.05). Additionally, specific airway resistance (sRaw) was 
significantly greater following the EC smoking tasks than during FAM (FAM: 7.18 ± 1.60 cmH2O∙s; EC-: 
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8.65 ± 2.09 cmH2O∙s; EC+: 8.41 ± 1.77 cmH2O∙s; p = 0.008, η2p = 0.415). Significant decreases of 
specific airway conductance (sGaw) were observed following EC smoking task compared to FAM (FAM: 
0.146 ± 0.03 cmH2O-1∙s-1; EC-: 0.123 ± 0.03 cmH2O-1∙s-1; EC+: 0.125 ± 0.03 cmH2O-1∙s-1; p = 0.025, η2p = 
0.390) 
 
Cardiometabolic Responses to Exercise 
Oxygen consumption (V̇O2) and carbon dioxide production (V̇CO2) increased from rest to peak exercise (p 
< 0.05, η2p = 0.963; Figure 1). V̇O2peak (EC-: 3.11 ± 0.42 L∙min-1; EC+: 3.15 ± 0.56 L∙min-1; p = 0.655), as 
well as peak power (EC-: 261 ± 38 W; EC+: 270 ± 40 W; p = 0.081), were not different between conditions. 
However, time to exhaustion was greater in the EC+ condition compared with EC- (EC-: 9.66 ± 1.35 min; 
EC+: 9.97 ± 1.21 min; p = 0.036). When expressed as a percent of peak, V̇O2 (EC-: 49 ± 2 %; EC+: 47 ± 2 
%; p = 0.014, η2p = 0.510) was significantly different between conditions; however, absolute V̇O2 (EC-: 
1.51 ± 0.04 L∙min-1; EC+: 1.44 ± 0.05 L∙min-1; p = 0.172, η2p = 0.196) and relative V̇O2 (EC-: 17.82 ± 0.71 
mL∙kg-1∙min-1; EC+: 17.49 ± 0.599 mL∙kg-1∙min-1; p = 0.524, η2p = 0.047) were not different between 
conditions. A condition by intensity interaction for relative V̇O2 was detected (p = 0.050, η2p = 0.150); 
however, post hoc analysis of these data did not elucidate where the differences existed. There was no 
condition by intensity interaction of absolute oxygen consumed (p = 0.165, η2p = 0.159) or oxygen 
consumption as a percent of peak (p = 0.098, η2p = 0.169). While V̇CO2 change with intensity (p < 0.001, 
η2p = 0.960), there was no difference of condition (EC-: 1.52 ± 0.05 L∙min-1; EC+: 1.45 ± 0.06 L∙min-1; p = 
0.314, η2p = 0.112) or of condition by intensity (p = 0.127, η2p = 0.186). 
Heart rate increased with exercise intensity (p < 0.001, η2p = 0.950), yet no differences were observed 
between EC- and EC+ (EC-: 121 ± 4 beats∙min-1; EC+: 122 ± 5 beats∙min-1; p = 0.450, η2p = 0.065) or a 
condition by intensity interaction (p = 0.779, η2p = 0.059; Figure 2).  O2 pulse also increased throughout the 
incremental exercise (p < 0.001, η2p = 0.950). While O2 pulse was greater throughout the incremental 
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exercise test during EC- compared with EC+ (EC-: 11.68 ± 0.40 mL∙beats-1; EC+: 11.03 ± 0.44 mL∙beats-
1; p = 0.043, η2p = 0.381), a condition by intensity interaction was not observed (p = 0.157, η2p = 0.150). 
Ventilatory Responses to Exercise 
V̇E, VT, and ƒB increased with intensity (p < 0.001, η2p > 0.9). However, V̇E and breathing pattern were not 
different between EC- and EC+ (V̇E: p = 0.059, η2p = 0.289; VT: p = 0.627, η2p = 0.077; ƒB: p = 0.110, η2p = 
0.192; Figure 3). The duration of inspiration (Ti), duration of expiration (Te), and the ratio of Ti to the total 
duration of a breath (Ti/Ttot) were all found to change with increasing intensity (p < 0.001; Figure 4); 
however, no differences were observed between conditions (p > 0.100, η2p > 0.020) or a condition by 
intensity interaction (p > 0.100, η2p > 0.080). 
Estimates of inspiratory and expiratory WoB during each stage were found to increase in accordance with 
increased ventilatory demand (p < 0.001, η2p > 0.900; Figure 4). Both estimates of WoB were not different 
between conditions (p > 0.800, η2p < 0.050) or a condition by intensity interaction (p > 0.600, η2p < 0.040). 
Operational lung volumes 
EELV decreased significantly with increased demand of ventilation (p < 0.001) while EILV simultaneously 
increased (p < 0.001). No effect of condition was observed in operational lung volumes (EILV: p = 0.724, 
η2p = 0.016; EELV: p = 0.103, η2p = 0.298). Further, no interaction of condition by intensity was observed 
in operational lung volumes (p > 0.6, η2p <0.08). EFL was not found to be different between conditions 
(EC-: 40 ± 21; EC+: 34 ± 29; p = 0.600) and limitations were not observed prior to subject’s peak exercise 
stage. 
Perceptual Responses to Exercise 
RPB (p = 0.213, η2p = 0.166), RPU (p = 0.158, η2p = 0.209), and RPE (p = 0.582, η2p = 0.035) were not 
different by condition, nor was a condition by intensity interaction found to be significant (RPB: p = 0.536, 
η2p = 0.066; RPU: p = 0.490, η2p = 0.082; RPE: p = 0.400, η2p = 0.103; Figure 6). Following volitional 
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exhaustion, a visual analog scale had subject rate their emotional responses pertaining to their peak RPB 
during exercise (EC- peak RPB = 6.8 ± 1.5, EC+ peak RPB = 7.1 ± 1.6). No differences were found between 
conditions when comparing VAS measurements of unpleasantness (p = 0.124, η2p = 0.242), anxiety (p = 
0.571, η2p = 0.037), depression (p = 0.647, η2p = 0.024), anger (p = 0.377, η2p = 0.088), frustration (p = 
0.424, η2p = 0.072), fear (p = 0.480, η2p = 0.057; Figure 6) 
Discussion 
The findings of this experiment demonstrate that acute usage of a first generation EC has minimal 
influence on pulmonary function and a minimal effect on cardiorespiratory and metabolic responses 
during exercise, as suggested by differences in relative V̇O2 and O2pulse, as surrogate of stroke volume25. 
Given the lack of differences between the EC- and EC+ trials, these data suggest that, during incremental 
exercise, the introduction of EC vapors does not elicit a significant effect on the oxidative capabilities of 
cells, nor does EC elicit significant alterations to ventilatory dynamics.  
Pulmonary function 
Decrements to pulmonary function were not observed in response to the acute EC exposure which agrees 
with previous literature6-8. FVC was different between FAM and the EC smoking task trials (EC- and 
EC+) and not between EC- and EC+. The significant difference between FAM and the EC challenges, 
either EC- or EC+, seem to suggest that the inspiratory maneuver (i.e., EC smoking task inspiratory 
maneuver) was the stimulus that altered subjects as compared to FAM. Furthermore, lung volumes were 
maintained regardless of trial which would agree with previous findings. 
Additionally, measurements of airway resistance and specific airway resistance were found to be 
significantly different between the FAM and EC smoking task trials (EC- and EC+), which suggests that 
the task itself, and not the EC vapors, was sufficient to alter airway resistance. Indeed, these data are 
consistent with previous literature that measured resistance in EC users 6,7. Interestingly, our subjects 
were all males while other EC studies include females, who anatomically have increased resistance due to 
78
decreased airway diameter, in airway resistance measures6,7. Therefore, our findings agree that Raw, 
sRaw, and Gaw are affected following EC smoking task; however, our absolute values are only indicative 
of male reactions to EC stimulus as females were not a part of the cohort. A study that used both males 
and females concluded that airway resistance at low frequency impulse oscillometry, or the larger 
airways, was affected to a greater extent in a EC smoking trial comparing EC+ to EC-; however, the EC- 
trial did not elicit the same degree of decrement and was found to not change between pre and post EC- 
trial6. This does not support the findings of our study as both EC- and EC+ were different from the FAM 
trial. Additionally, we did not observe differences between EC- and EC+. Indeed, impulse oscillometry is 
a more advanced measurement than that of the current study and must be carefully considered when 
comparing airway resistance. 
Incremental Exercise Test 
It must be acknowledged that there was no familiarization with the peak exercise test, therefore, main 
effect of condition would only be measured between EC- and EC+. As reported, a condition by intensity 
interaction was observed for relative V̇O2. These data agree with general trends of oxygen consumption as 
that of smokers versus nonsmokers with non-smokers having a slightly increased oxygen consumption at 
submaximal work rates26. While relative oxygen consumption was significant, the lack of significance in 
absolute V̇O2 is troubling as this points to subtle changes or either mass and/or O2 consumption.  
Measurements of metabolic gases revealed that O2 consumption as a percent of V̇O2peak were different 
depending on the EC smoking task (i.e., EC- versus EC+). When compared with the acute effects of 
traditional cigarettes, similar trends were observed where O2 pulse was reduced while V̇O2 was 
maintained26,27. Additionally, no changes were noted for V̇CO2 between conditions, which is comparable 
to similar studies previously performed using traditional cigarettes26. The lack of differences in V̇CO2 
does agree with the lack of differences in absolute V̇O2, as differences in one would suggest alterations to 
the other given the relationship of the gases during an incremental exercise test. 
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Interestingly, HR did not have a significant difference between conditions at any relative or absolute work 
rate. These data are contradictory to Yan and D’Ruiz who compared varying EC and observed an 
increased resting HR20,28. Consequently, though the HR was not significantly different, the O2 pulse was 
decreased in the EC+ challenge condition compared with EC- suggesting that stroke volume could be 
influenced during acute EC exposure. These data are conflicting with traditional tobacco cigarettes as 
these have been shown to increase cardiac output, stroke volume, and heart rate29. Potential differences in 
findings between studies can be attributed to differences in technique (e.g., measured vs estimated) and 
chemical composition. Nicotine concentrations of traditional tobacco cigarettes have a range of 7.17-
28.86 mg30, and our subjects did not receive the full 24 mg of nicotine as each subject only performed 20 
inspiratory doses of the EC. 
Operational lung volumes, when expressed as EELV and EILV absolute or relative to TLC, were 
conserved regardless of challenge. Further, the timing components of breathing were not different 
between the EC- and EC+ trials. These findings suggest that after performing the EC smoking task, 
individuals will exhibit similar breathing patterns, as well as breathing mechanics. Given these results, it 
would be beneficial to include a FAM trial to the exercise as this would elucidate if the EC smoking 
challenge was the stimulus for altered breathing mechanics, or if mechanics are conserved regardless of 
the increased Raw, sRaw, and decreased sGaw. 
Finally, no differences between conditions and no condition by intensity interaction of RPB, RPU, or 
RPE suggest that the EC smoking task did no invoke conscious alterations to perception. Yet, our group 
of subjects included previous smokers. The study design eliminated any potential alterations given the 
repeated measures design as separate groups could have skewed the findings since current and past 
smokers experience greater frequency of dyspnea symptoms31. Additionally, no differences in the 
affective dimension of dyspnea which tends to be conserved across studies unless a severe pathological 





These findings are among the first to examine the acute exposure to electronic cigarettes and the 
influence, and lack thereof, on incremental exercise. While previous literature has assessed the pulmonary 
function post EC exposure, our study has elucidated that the increased airway resistance experienced 
following an EC exposure could be due to the inspiratory challenge. Additionally, we find that there are 
no alterations to exercise capacity, as expressed by peak work rate, or to the aerobic capacity of 
individuals following acute EC usage. Finally, the lack of differences in operational lung volumes, 
breathing mechanics, breathing pattern, and estimates of the work of breathing suggest that there are no 
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Table 1. Subject characteristics (n=10) 
Height, cm 182.4 ± 9.7 
Weight, kg 83.9 ± 13.2 
BMI, kg∙m-2 25.2 ± 3.6 
IPAQ, MET⸳min∙week-1 3474 ± 2196 
Smoking history, packs∙yr-1 0.13 ± 0.44 
BMI, body mass index; IPAQ, International Physical Activity Questionnaire.  Measurements reported 
are from the familiarization visit. Measurements of height were kept constant across visits. Weight and 
BMI were not different between visits (p > 0.05). Smoking history includes all subjects; however, only 
5 subjects reported having a history of smoking. 
84
Table 2. 
Table 2. Pulmonary Function (n=10) 
FAM EC- EC+ 
Value %Pred Value %Pred Value %Pred p value η2p 
FEV1, L 5.05 ± 0.75 104 ± 7 4.96 ± 0.79 102 ± 7 4.90 ± 0.76* 101 ± 9* 0.111 0.217 
FVC, L 6.27 ± 0.83 107 ± 5 6.10 ± 0.92 104 ± 5 6.07 ± 0.86 104 ± 5 0.010 0.399 
FEV1/FVC, % 81 ± 5 94 ± 6 81 ± 6 95 ± 6 81 ± 6 94 ± 7 0.689 0.040 
PEF, L∙s-1 11.09 ± 1.42 107 ± 10 10.81 ± 1.05 104 ± 9 10.45 ± 0.89 101 ± 8 0.133 0.224 
TLC, L 7.62 ± 1.36 101 ± 11 7.74 ± 1.15 103 ± 8 7.59 ± 1.28 101 ± 10 0.320 0.119 
FRC, L 3.96 ± 0.84 117 ± 20 3.92 ± 0.92 116 ± 23 3.74 ± 0.87 111 ± 22 0.270 0.135 
FRC/TLC, % 52 ± 8 109 ± 17 50 ± 7 104 ± 13 49 ± 7 102 ± 13 0.410 0.094 
RV, L 1.36 ± 0.68 83 ± 39 1.64 ± 0.62 101 ± 36 1.43 ± 0.68 88 ± 40 0.090 0.235 
RV/TLC, % 17 ± 7 21 ± 7 18 ± 7 0.141 0.196 
FAM, familiarization; EC-, placebo EC smoking task; EC+, electronic cigarette EC smoking task; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; 
PEF, peak expiratory force; TLC, total lung capacity; FRC, functional residual capacity; RV, residual volume; η2p, partial eta squared. * significantly different from 
FAM. p values are univariate comparisons of the values, not % pred, andη2p is the effect size of the comparison. 
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Figure 1. Placebo condition (EC-) and experimental condition (EC+) are represented as black squares and 
circles, respectively. Volume of oxygen consumed (V̇O2; A) versus stage was not different between 
condition (p = 0.172). Produce volume of carbon dioxide (V̇CO2; B) was not found to be significantly 
different between conditions (p = 0.314). V̇CO2 relative to V̇O2, or respiratory exchange ratio, was not 
different between conditions (p = 0.575). 
Figure 2. Placebo condition (EC-) and experimental condition (EC+) are represented as black squares and 
circles, respectively. Heart rate (A) was not different between conditions (p = 0.450). Additionally, the 
oxygen pulse (O2 pulse; B) was lower in the EC+ challenge (p = 0.043). 
Figure 3. Placebo condition (EC-) and experimental condition (EC+) are represented as black squares and 
circles, respectively. Tidal volume (VT; A) was not different between conditions (p = 0.588). Breathing 
frequency (ƒB; B) was not different between conditions (p = 0.598). Ventilation (VE; C) was not different 
between conditions (p = 0.951). Ventilatory efficiency (D), expressed as ventilation relative to expired 
volume of carbon dioxide (VE/VCO2), was not found to be different between conditions (p = 0.331). 
Figure 4: Placebo condition (EC-) and experimental condition (EC+) are represented as black squares and 
circles, respectively. Maximal mouth pressures were measured during inspiration (Pi; A) and expiration 
(Pe; B) and were not different between conditions (Pi: p = 0.749; Pe: p = 0.453). The duty cycle of 
breathing relative to total breath duration (Ti/TTotal; C) was not different between conditions (p = 0.683). 
Expired duration (Te; D) was not different between conditions (p = 0.181). Rest consisted of N = 9 while 
exercise consisted of the entire sample (N = 10). 
Figure 5: Placebo condition (EC-) and experimental condition (EC+) are represented as squares and 
circles, respectively. End-inspiratory and end-expiratory volumes (EILV and EELV, respectively) are 
shown versus stage of the test (A) and versus ventilation (B) where black markers are EELV and white 
markers are EILV. Neither EILV nor EELV were significantly different between conditions (p = 0.244 
and p = 0.864, respectively). Rest consisted of N = 9 while exercise consisted of the entire sample (N = 
10). 
Figure 6: Placebo condition (EC-) and experimental condition (EC+) are represented as black squares and 
circles, respectively. During exercise, ratings of perceived breathlessness (RPB; A), unpleasantness 
(RPU; B), and exertion (RPE; C) were recorded. A visual analog scale (D) was used to assess 
unpleasantness of breathing, depression, anxiety, frustration, anger, and fear associated with peak ratings 
of perceived breathlessness. No differences were observed between conditions of RPB, RPU, or RPE (p = 
0.213, p = 0.158, and p = 0.102, respectively). Visual analog scales were not different between condition 
(unpleasantness, p = 0.124; anxiety, p = 0.571; depression, p = 0.647; anger, p = 0.377; frustration, p = 
0.424; fear, p = 0.480). 
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Appendix B.a.: Informed consent, formaldehyde study 
Appalachian State University 
Informed Consent for Participants in 
Research Projects Involving Human Subjects 
Title of Project: Effect of Formaldehyde Exposure on Pulmonary and Vascular 
Function 
IRB Study #: 
Principal Investigators (co-PIs): Stephen Ratchford, Ph.D. 
Jonathon Stickford, Ph.D. 
Ashley Goodman, Ph.D. 
Research Assistants: Marc Augenreich Email: augenreichma@appstate.edu 
Val Province  Email: provincevm@appstate.edu 
Sera Denlea  Email: denleasc@appstate.edu 
Taylor Lovci  Email: lovcit@appstate.edu  
Kennedy Williams Email: williamska8@appstate.edu 
Kyle Kimball  Email: kimballkc@appstate.edu 
This is to confirm that I,      , have been given the 
following information with respect to my participation in a research study under the supervision 
of Drs. Stephen Ratchford, Jonathon Stickford, and Ashley Goodman, to which Marc 
Augenreich, Val Province, Taylor Lovci, Sera Denlea, Kennedy Williams, and Kyle Kimball 
may be assisting. 
1. Purpose of the study: Dr. Ratchford and his colleagues are conducting a series of
research studies to learn more about lung and blood vessel health when individuals come
in contact for formaldehyde (FA), a typical chemical used for preserving cadavers in
anatomy classrooms.
The purpose of this work is to better understand lung and blood vessel health and the
contributing factors that could cause lung and blood vessel function to become impaired
with chemical exposure. The long-term goal of this work is to find optimal strategies to
minimize the impact of FA among those with acute and chronic exposure to FA.
2. Inclusion Criteria: You may participate in the study if the following apply to you:
• Over 18 years old
• Are Healthy
• Nonsmoker
Exclusion Criteria: You should not participate in this study if any of the following 
apply to you: 
• Under 18 years old
• Relatively unhealthy
• Smokers
• Pregnant or those who are trying to become pregnant
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3. Procedures: Please read the descriptions of each study and experimental visits, writing 
your initials in the space provided. While you may agree to participate in one or more 
procedures associated with one or more of the following protocols, you will always have 
the right to forego one or all procedures associated with this study. 
 
PRELIMINARY SCREENING DAY (0.5-1 hours). A signed consent form will be obtained 
prior to any research procedures. A screening questionnaire will be filled out that will include 
questions concerning risks such as: age, family health history, smoking, hypertension, 
hypercholesterolemia, and physical activity and allergies (iodine, latex, drugs, etc).    
 
Experimental Visits (2 hours/visit, 4 visits total). 
 
Lung and blood vessel function testing will be performed before and after acute and (up to 3) 
repeated exposures to FA within a week at the start and end of . Typically, acute exposures 
may occur during the first-class period of a donor-based classroom experience. Repeated 
exposures may occur over multiple class meetings within the initial week of a donor-based 
classroom experience. A single visit encompasses lung and blood vessel function testing 
before and after acute FA exposure. Thus, we are asking you to complete two visits within a 
single week to perform lung and blood vessel function testing.  
 
Rational for Flexibility in Repeated Exposure Visits. Several types of classroom FA exposure 
sites are being investigated in this study. Duration and frequency of exposure will vary with 
each course. For example, Athletic Training Cadaver Dissection at Appalachian State 
University will meet for 4 hours each day for a time-intensive 5 weeks, while undergraduate 
anatomy courses may only meet for ~2 hours each week over the course of 16 weeks. Several 
students will be investigated among a variety of repeated exposures and FA exposure 
concentrations to gauge the effect of multiple FA exposures. Ideally, these follow-up visits will 
be at regular intervals throughout the subject’s predetermined exposure duration (e.g. once a 
month for 3 months). Therefore, students may be studied up to 3 different times following an 
initial exposure which may be as frequent as once a week or as infrequent as once a month 
based on subject willingness, availability, and investigative team availability for frequent 





Figure 1. Example schematic of testing acutely and upon repeated formaldehyde (FA) 
exposures at Elon University and Appalachian State University where FA concentrations 
range from 0.04-0.13 ppm. Prior to each day of testing, resting pulmonary and vascular 
function assessments will be performed on participants as well as immediately following FA 
exposure. BD, Blood Draw; FA Exp, Formaldehyde Exposure; h, hour; P/V A, 
Pulmonary/Vascular Assessments; w, week. 
 
 
Techniques and Measurements 
 
Blood sampling: A venous blood sample (up to 24ml) will be drawn from the arm on two 
occasions during each visit (before and after FA exposure). Venous blood will be collected 
using standard techniques while at rest to test for markers of inflammation and oxidative 
stress.  
 
Lung Function Testing. Lung function will be tested noninvasively in accordance with the 
standards set by The American Thoracic Society and The European Respiratory Society. The 
test will measure the volume of air contained within the lungs, as well as the speed at which 
you can empty your lungs. You will be asked to perform the tests in a seated, upright position 
while wearing nose clips. Measurements will include: forced vital capacity (FVC; the amount 
of air exhaled forcefully and quickly after inhaling as much as you can), forced expiratory 
volume in one second (FEV1; the amount of air expired during the first second of the FVC 
test), peak expiratory flow (PEF; the fastest rate that you can force air out of your lungs), and 
forced expiratory flow (FEF; the rate of air flow during the middle half of the FVC test). These 
measurements are accepted as a general tool for respiratory health and provide an indication 
of how well the lungs are working. These tests will typically take 15-20 minutes. 
 
Blood Vessel Function Testing. Blood vessel function will be measured at rest while laying 
down.  Blood vessel function tests may include flow mediated dilation (FMD) and passive limb 
movement (PLM), two clinically relevant tests to investigate vascular function and nitric oxide 
bioavailability-- a potent vasodilatory pathway in blood vessels which decreases with chronic 
inflammation, reactive oxygen species, and cardiovascular disease. Additionally, pulse wave 
velocity (PWV) may be assessed to determine any alterations to arterial stiffness, another 
clinically relevant test which has been well documented in healthy, aged, and clinical 
populations and which may allow for cross comparison to other human models of 
inflammation-related vascular dysfunction. Dr. Ratchford has extensive experience in this 
area and has mobile equipment specifically for the purpose of field-based experiments such 
as those proposed here. 
These tests will typically take 30 minutes. 
 
Repeated exposures (up to 3 follow up visits) may occur within the same week as the acute 
exposure or may take place throughout the semester. These additional visits may be decided 
based on preliminary findings, subject availability and willingness to participate in ongoing, 
longitudinal data tracking, and investigative team availability and logistical constraints with 
coordinating between two university settings. 
Exercise: Described exercise modalities are small muscle mass and therefore only minimally 
tax the heart and lungs, even at maximal efforts.  All exercise testing may be completed in 
Leon Levine Hall or a convenient meeting location (place of residence, clinical office, or other 
private assessment facility) under investigator supervision. 
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Flow-mediated vasodilation (FMD) test: A blood pressure cuff will be placed on the upper 
arm and inflated to >250 mmHg for five minutes to partially occlude the forearm. Ultrasound 
Doppler measurements will be made in the brachial artery to evaluate FMD upon cuff release. 
Dr. Ratchford has direct experience with this technique (1). 
Heart Rate: A standard ECG will be used to measure heart electrical activity, with heart rate 
determined from R-R interval (lead II).  
Limb Blood Flow: An ultrasound Doppler system (Logiq e, GE Medical Systems, Milwaukee, 
Wisconsin, USA) equipped with two linear array transducers operating at an imaging 
frequency of 7-8 MHz and 12-14 MHz will be used for the leg and arm, respectively. Vessel 
diameter will be determined at a perpendicular angle along the central axis of the scanned 
area, where the best spatial resolution is achieved.  The brachial artery (BA) of the right arm 
will be insonated approximately midway between the antecubital and axillary regions, medial 
to the biceps brachii muscle. The blood velocity profile will be obtained simultaneously using 
the same transducers with a Doppler frequency of 4.0-5.0 MHz, operated in the high-pulsed 
repetition frequency mode (2-25 kHz) with a sample depth of 1.5-3.5 cm and the probe 
maintained at an insonation angle of 60° or less. Sample volume will be maximized according 
to vessel size and centered, verified by real-time ultrasound visualization of the vessel. Using 
artery diameter and Vmean, blood flow is calculated as: blood flow (ml/min) = Vmean · π · (Vessel 
Diameter/2)2 · 60. At all sample points, arterial diameter and angle-corrected, time-averaged, 
and intensity-weighted mean blood velocity (Vmean) values can be calculated using 
commercially available software (Logiq e). Ultrasound digital images and velocity spectra 
segments of five minutes will be recorded and saved to the GE Logiq e hard drive for off-line 
image and waveform analysis. Dr. Ratchford has extensive experience with this methodology. 
Non-invasive arterial blood pressure: Systemic arterial blood pressure (ABP) will be 
measured non-invasively on a continuous basis using finger photoplethysmography 
(Finometer, Ohmeda, Madison, WI, USA). The finometer cuff is placed on the middle finger of 
the right hand and is supported on a modified surgical stand adjusted to position the finger 
cuff at heart level.  
Passive Leg Movement: Participants are moved into an upright sitting position for ∼10 min 
before the start of the data collection and remain in this position throughout the entire protocol. 
The protocol consists of 60-s of resting baseline data acquisition followed by a 2-min bout of 
passive leg extension. PLM is achieved by a member of the research team moving the 
participant's lower leg through a range of motion, defined by 90° and 180° knee joint angles, 
at a rate of 1 Hz. Throughout the protocol, the non-moving leg remains fully extended and 
supported. Real-time feedback to the investigator is provided by a metronome to maintain the 
cadence. Before commencing, and throughout the protocol, participants are encouraged to 
remain passive and resist any urge to assist with leg movement. To avoid a startle reflex and 
active resistance to the PLM, participants are made aware that the assessment will start in 
the next minute, but to minimize the chance of an anticipatory response, they are not informed 
of exactly when movement will begin (2).  There are no known risks of this procedure. 
 
Pulse-Wave Velocity (PWV) Test: Participants with be in the supine position in a quiet room 
for ~10 min before the start of data collection. An ascending aortic pressure waveform is 
derived from the carotid artery waveforms using applanation tonometry with a high-fidelity 
micromanometer. The carotid-femoral aortic PWV may be determined using the Sphygmocor 
XCEL system by sequentially recording electrocardiographic-gated carotid and femoral artery 
waveforms. Distances from the carotid sampling site to the suprasternal notch and from the 
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suprasternal notch to the femoral artery site are measured as straight lines between the points 
on the body surface using a tape measure. The time (t) between the onset of femoral and 
carotid waveforms is determined as the mean from 10 consecutive cardiac cycles. The PWV 
is calculated from the distance between measurement points (D) and the measured time delay 
(t) as follows: PWV = D/t (m/sec), where D is distance in meters and t is the time interval in 
seconds. 
 
Dr. Ratchford has extensive experience in all described procedures, and he or a 
qualified/trained member of the research team will perform all necessary procedures to ensure 
safety and validity of assessments. 
 
 
4. Risks and Discomforts: 
 
All of the research methodology has been conducted on hundreds of subjects in sessions 
similar to the study proposed.  
 
Blood sampling: There is a possibility of bruising from blood draws.  It should be noted that all 
blood collection procedures will be performed in a clean environment by qualified personnel 
(i.e., nurse or phlebotomist).  The safety of the participant is of utmost importance during the 
blood draws, therefore standard precautions will be used including the cleaning of the 
venipuncture site with alcohol, the use of new sterile disposable needles/syringes and 
changing of disposable gloves in between participants. 
 
Lung function testing: Risks associated with lung function testing are minimal. There is a 
possibility of discomfort while performing the forced exhalation maneuver. 
Exercise: There is a very small risk that performing exercise reveals a problem with your heart 
(exposing you to the risk of a heart attack or irregular heartbeat that could require 
hospitalization), and particularly with the blood vessels which supply the heart (coronary 
arteries). These problems could range from insufficient blood flow to the heart (myocardial 
ischemia), heart attack (myocardial infarction), or irregular heart beat (arrhythmia), and these 
serious heart conditions could be fatal. Symptoms for these conditions would be pain in the 
chest, excessive shortness of breath, or abnormalities on the electrocardiogram (ECG) during 
exercise. This procedure (the ECG) is performed to be as sure as possible that there are no 
active heart problems during the study. However, if these problems develop, exercise will be 
stopped immediately and you may be referred to your local physician for proper follow-up.  
Finally, the performance of exercise may also result in muscle soreness that might last several 
days. 
Flow-mediated vasodilation (FMD) test: Minor discomfort may be associated with the five-
minute occlusion period caused by the blood pressure cuff. However, trained research 
personnel will make sure that the blood pressure cuff is completely deflated as soon as the 
measurement is completed. 
Handgrip Exercise: Small muscle mass exercise minimizes chances of increasing heart rate 
and blood pressure, but it may still increase these by ~20bpm or ~40mmHg, respectively. For 
this reason, these measurements are monitored continuously and the test will be terminated 
if systolic blood pressure increases above 220 mmHg. There is also a small chance of hand 
discomfort when isometrically squeezing the hand dynamometer. If the hand grip exercise 
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becomes too uncomfortable, the subject has the ability to withdraw from the exercise at any 
time. 
Handgrip Exercise MVCs: There is a small chance of hand discomfort when isometrically 
squeezing the hand dynamometer. If the hand grip exercise becomes too uncomfortable, the 
subject has the ability to withdraw from the exercise at any time. 
Limb Blood Flow: Doppler ultrasound is used to assess limb blood flow. This is a non-invasive 
assessment and does not pose any known risk other than minor discomfort from moving the 
ultrasound probe over the skin. Skin tears rarely occur while moving a doppler ultrasound 
probe over sensitive/fragile skin regions (e.g. morbidly obese individuals with skin folds) and 
is no more common than what a subject with this type of skin would normally experience in 
daily life. 
Near Infrared Spectroscopy (NIRS): There is no known risk associated with using this device 
for it is intended use. 
Non-invasive arterial blood pressure: There may be minor discomfort during the measurement 
of arm blood pressure and during the cuff occlusion due to the inflation of the blood pressure 
cuff. 
Passive Leg Movement: Individuals with knee pain or joint impairments may experience mild 
discomfort during the movement through 90-degree range of motion of the knee joint. Also, 
individuals with peripheral edema or peripheral neuropathy may experience some discomfort 
while the ankle is help in place by a member of the investigative team who is assigned to be 
the leg mover. For this reason, these individuals will be excluded from this test. 
 
Pulse-Wave Velocity (PWV) Test: Apart from the possibility of some minor discomfort 
associated with the slight pressure that is applied over the artery, there are no significant risks 
associated with this test. 
 
Reproductive Risks: While this study is strictly characterizing FA exposure, exposure to FA 
may harm an unborn child. Pregnant women must not take part in this study, nor should 
women who plan to become pregnant during the study. Women who are at risk of pregnancy 
will be asked to have a pregnancy test before taking part to exclude the possibility of 
pregnancy. If you could become pregnant you must use an effective contraceptive during the 
course of this study. Acceptable methods of birth control include oral/topical/injected 
contraceptives, intra-uterine devices, and barrier methods.  If you become pregnant while 
taking part in the study, you must immediately tell your research doctor, where options will be 
discussed with you at that time. Whether or not you remain on study treatment, we will follow 
the outcome of your pregnancy and we will continue to follow you according to the study plan. 
 
5. Benefits: 
a. To You: We will be able to share any data collected on you during the study. However, 
we will not be able to interpret any clinical results we obtain from you. While this data 
may be helpful in assessing your physical condition, members of the investigative team 
do not have the right to make clinical conclusions regarding your health status as it 
pertains to the above-mentioned investigations.  
b. To Society: This study will provide helpful information to those exposed to various 
levels and durations of FA which can be helpful for understanding the impact on lung 
and blood vessel health among the general population. 
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6. Alternative procedures that could be utilized:  There are not any alterative
procedures. The procedures outlined in this document are the only interventions and
assessments the investigative team will ask of you. The procedures used in this study
are frequently used in research and are the most appropriate methods to accomplish
the goals of this research.
7. Statement of confidentiality: Volunteers are coded using the first two letters of your
first name and first two letters of your last name for statistical analyses. All records are
kept in a secure, physically-locked and/or password-protected location, and only the
study investigators will have access to the data. All records associated with your
participation in the study will be subject to the university confidentiality standards and
in the event of any publication resulting from the research no personally identifiable
information will be disclosed. Your information will be combined with information from
other people taking part in the study. When we write up the study to share it with other
researchers as well as the scientific and medical community, we will write about the
combined information. You will not be identified in any published or presented
materials. To ensure that your information is kept confidential, identification codes but
not names will be used on all documents. The Office of Human Research Protections
in the U.S. Department of Health and Human Services, the U.S. Food and Drug
Administration (FDA), the Office for Research Protections at Appalachian State
University and the Institutional Review Board may review records related to this
project.
8. Right to ask questions: Stephen Ratchford, Ph.D. (828-262-7630) or
RatchfordSM@AppState.edu with questions, complaints, or concerns about this
research. If you have any questions about your rights as a research subject, please
contact the IRB Administrator at the Appalachian State University Institutional Review
Board Office at (828) 262-2692, irb@appstate.edu.
9. Compensation for your time:
You will be compensated at a rate of $20 for each visit. For completion of all mentioned 4 
visits, you will receive $80 after the study is completed or prorated based on participation. 
10. Injury Clause: In the unlikely event you become injured as a result of your
participation in this study, standard emergency procedures will be followed. If you get
hurt or sick when you are not at the research site, you should call your doctor or call
911 in an emergency. If your illness or injury could be related to the research, tell the
doctors or emergency room staff about the research study, the name of the Principal
Investigator (Stephen Ratchford), and provide a copy of this consent form if possible.
Please call the PI (Stephen Ratchford, Ph.D. 828-262-7630). You will be responsible
for any costs for medical care not paid by your insurance company. No other
compensation is offered by Appalachian State University.  By signing this document,
you are not waiving any legal rights that you have against Appalachian State University
for injury resulting from negligence of the University or its investigators.
11. Voluntary participation: Your participation in this study is strictly voluntary and will
not affect your relationship with the study team, work, academic, or clinical staff. You
may withdraw from this study at any time by informing the research personnel. You
may decline to answer certain questions and may decide not to comply with certain
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procedures. However, your being in the study may be contingent upon answering 
these questions or complying with the procedures. The researcher may end your role 
in the study without your consent if the researcher deems that your health or behavior 
adversely affects the study or increases risks to you beyond those approved by the 
Institutional Review Board and agreed upon by you in this document. You have been 
given an opportunity to ask any questions you may have, and all such questions or 
inquiries have been answered to your satisfaction. 
Informed Consent Signatures 
You must be 18 years of age or older to take part in this research study. If you agree to take 
part in this research study and have read the information outlined above, please sign your 
name and indicate the date below.  You will be given a copy of this signed and dated consent 
form for your records. 
Participant, Printed Name Participant, Signature 
Date 
I, the undersigned, have defined and explained the studies involved to the above 
volunteer. 
Consent Obtainer, Printed Name Consent Obtainer, Signature 
Date 
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Appendix B.b.: Informed consent, electronic cigarette study 
Appalachian State University 
Informed Consent for Participants in 
Research Projects Involving Human Subjects 
 
 
Title of Project: Respiratory limitations, exercise tolerance, and exertional 
dyspnea following acute electronic cigarette use 
IRB Study #: 16-0297 
  
Principal    
Investigator:  Jonathon Stickford, Ph.D. Email: stickfordjl@appstate.edu 
     
Research Assistants: Erica Larson, B.S.  Email: larsone@appstate.edu 
   Jayvaughn Oliver, B.S. Email: oliverjt@appstate.edu 
   Rylie Bragg   Email: braggre@appstate.edu 
     
 
This is to certify that I,                                                                             have been given the following 
information with respect to my participation as a volunteer in a program of investigation 
under the supervision of Jonathon Stickford, Ph.D. to which Erica Larson, B.S, Jayvaughn 
Oliver, B.S., and Rylie Bragg may be assisting. 
 
1. Purpose of the study: 
Electronic cigarettes (EC) are devices intended to deliver an aerosol containing nicotine and 
possible flavorings. They are marketed as a method for quitting tobacco smoking, as a 
healthier alternative to tobacco smoking, and as a method to “smoke” in public spaces. Many 
teenagers and young adults are increasingly using the devices. Yet, these devices may alter 
breathing responses exhibited during exercise. Furthermore, the perception of 
breathlessness during exercise may be affected following EC usage.  
The primary objective of this study is to investigate the acute effects of EC use on breathing 
responses during exercise and the perception of breathlessness in young adults. The results 
of this study will help us to understand the health effects of acute EC use in young adults. 
 
2. Inclusion Criteria: You may participate in the study if the following apply to you: 
• Sex: Only males will be included in the study. Females will not be included due to the 
influence of the menstrual cycle on breathing responses. 
• Ethnicity: Any 
• Age: 18 – 25 years of age. The rationale for the cut-off point for the upper limit of this 
age range is that we wish most of our subjects to come from the college community, 
whereas older students may present different physiological and psychological 
responses than that of younger students.  
• Interest in participating in a research study investigating electronic cigarette use 
• Understand written and oral instructions in English 
• Provide informed consent 
• Available during times the data collection is offered. 
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• According to the American College of Sports Medicine (ACSM) exercise preparticipation 
recommendations, does not have known cardiovascular, metabolic, or renal disease, nor 
exhibits any signs or symptoms of cardiovascular, metabolic, or renal disease.  
• Lung function must be within a specific range (FVC > 80% of predicted, 2) FEV1 > 80% 
of predicted, and 3) FEV1/FVC x 100 > 75%) 
• You must not be a tobacco cigarette smoker. 
• You must be either a non-tobacco cigarette smoker (i.e., you can be an EC user) or naïve 
to EC. However, if you currently use EC, you must abstain from EC usage in the 12 hours 
prior to each laboratory visit. 
• You must participate in regular vigorous conditioning exercise such as running, jogging, 
aerobics, cycling, or swimming, less than two times per week to be included. You can be 
included if you participate in daily, unorganized physical activity. 
 
Exclusion Criteria (i.e., a list of criteria that if any one applies to you would prohibit 
you from being included in this study): 
• Known cardiovascular, metabolic or renal disease, or signs/symptoms suggestive of 
cardiovascular, metabolic or renal disease will exclude you from participation. 
Individuals with these characteristics require medical clearance before exercise 
participation, according to the 2015 ACSM preparticipation health screening 
recommendations.  
• If lung function is outside of a specific range, you will be excluded.  
• Current tobacco cigarette smoker.  
• If you participate in regular vigorous conditioning exercise such as running, jogging, 
aerobics, cycling, or swimming, two times or more per week, you will be excluded. Men 
who participate in daily, unorganized physical activity, will not be excluded. 
 
3. Procedures:. Please read the descriptions of each experimental day and write your 
initials in the space provided.  
 
You could be asked to repeat a trial, procedure, or test. This could happen for many 
reasons such as equipment failure, power outage, inconclusive test results, etc. 
However, you do not have to repeat a trial, procedure, and/or test if you do not wish to 
do so. 
 





________ initial      Prescreen: You may be telephoned by the Principle Investigator or a Research 
Assistant (see page 1) and asked screening questions to determine your eligibility for the study.  
 
Visit 1:  
 
________ initial      Consent and Questionnaires: Potential participants who meet inclusion 
criteria will be invited to a screening interview within the laboratory located off campus 
(Charleston Forge Research Site). At this screening visit, the study will be explained in-depth to 
you by the PI or a trained research assistant. You will be provided time to consider your options 
and get all questions answered - if you agree to participate, you will then provide your written 
informed consent. 
 
After you have provided consent (~30 minutes), you will be asked to complete questionnaires: 
1) a medical history questionnaire (~15 minutes) and 2) an exercise history questionnaire (~15 
minutes). 
 
________ initial      Body Composition: Following completion of the questionnaires, we will 
measure your height, weight, waist circumference, and body composition. Your percent body fat 
will be measured using a Bod Pod plethysmograph. You will sit in a chamber and may hear 
some clicking while air pressure changes to estimate your body volume. This piece of 
equipment estimates your body’s composition of fat and muscle by air movement. This is 
accomplished by measuring your mass (scale) and body volume (relationship between pressure 
and volume in chamber) and entering it into a calculation for fat mass and fat free mass 
(muscle). This is an extremely accurate method and presents no risk. These procedures will 
take ~15 minutes total 
 
________ initial      Pulmonary Function Testing (PFT) Familiarization: You will be asked to 
become familiar with tests of breathing function; the protocol will follow that described by the 
American Thoracic Society. These tests include measurement of the total volume of air your lungs 
can hold, the volume of air that you can push out with one maximal breath, the volume of air that 
you can forcefully breathe out in one second, and the maximum volume of air that you can breathe 
in 12 seconds. For all these procedures, you will wear nose clips and breathe through a disposable 
mouthpiece. These procedures will take ~30 minutes total. 
 
________ initial      Activity Assessment: You will be asked to wear an accelerometer around your 
waist over the 7 days following Visit 1in order to monitor your physical activity level. You will 
return the accelerometer during your next visit. 
 
Visits 2 and 3: 
 
________ initial      EC usage: You will be asked to inspire from an EC during each of these two visits. 
On one occasion the EC will contain a cartridge containing nicotine and flavoring. On the other 
occasion, the EC will not contain any nicotine or flavoring to serve as a control. You will inspire 
from the EC device once every 30 seconds for 10 minutes. A display on a computer screen will 
provide you with information on when to inspire from the EC. You will be asked to expire the 
vapor into a bag, which will be emptied following the testing session, to eliminate secondhand 
“smoke” exposure to yourself and study personnel. This will take ~15 minutes total. 
 
________ initial      Pulmonary Function Testing (PFT): You will be asked to perform tests of 
breathing function following EC use. The protocol will follow that described by the American 
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Thoracic Society. These tests include measurement of the total volume of air your lungs can hold, 
the volume of air that you can push out with one maximal breath, the volume of air that you can 
forcefully breathe out in one second, and the maximum volume of air that you can breathe in 12 
seconds. For all these procedures, you will wear nose clips and breathe through a disposable 
mouthpiece. These procedures will take ~60 minutes total. 
Visits 4 and 5: 
________ initial      EC Usage: You will be asked to inspire from an EC during each of these two visits. 
On one occasion the EC will contain a cartridge containing nicotine and flavoring. On the other 
occasion, the EC will not contain any nicotine or flavoring to serve as a control. You will inspire 
from the EC device once every 30 seconds for 10 minutes. A display on a computer screen will 
provide you with information on when to inspire from the EC. You will be asked to expire the 
vapor into a bag, which will be emptied following the testing session, to eliminate secondhand 
“smoke” exposure to yourself and study personnel. This will take ~15 minutes total. 
________ initial      Maximal Aerobic Capacity Exercise Test (V�O2max): You will be asked to 
perform a maximal exercise test following EC use. This test will measure your highest exercise 
capacity and is often described as a V�O2max test. You should be rested, well nourished, and 
hydrated for the test and avoid alcohol 12 hours before the test. Additionally, avoid caffeine and 
tobacco 3 hours before the test. Avoid significant exertion or exercise the day of testing and 
report any medication that you are using to the testing staff before the test. When you are ready 
to perform the test, the investigators will help with necessary adjustments to testing equipment 
to assure your comfort. You will be fitted with a rubber mouthpiece and nose clip. This procedure 
will require ~45 minutes total, with exercise lasting approximately 15 minutes. 
Cycling Protocol 
You will perform cycling exercise on a stationary bicycle. Prior to exercise, you will rest sitting 
on the bike with both hands on the handle bars for 5 minutes. After this rest period you will 
warm up at a light intensity of 30 Watts (W) using a cadence of 60 RPM for 5 minutes. The work 
rate will then be increased by 30W every minute until volitional exhaustion or signs/symptoms 
prohibit further exercise testing. During each minute of the test, we will measure your 
physiological responses (e.g., heart rate, VO2, etc.) and perceptual responses (e.g., ratings of 
perceived breathlessness, unpleasantness of breathlessness, and perceived exertion). You will 
be asked to “rate your breathing” by pointing with your finger to a number on a scale (Borg 0-
10), which will represent your perceived level of breathlessness. The number will be repeated 
out loud in order to confirm your choice. During the exercise you may have an even stronger or 
greater intensity of breathlessness than you have previously experienced. If this occurs, you 
should point to the word “maximal” if the severity is greater than 10. After the mouthpiece is 
removed, you can tell us the number. Following completion of the test, you will perform a brief 
light intensity cool-down.  
Flow-Volume Loops 
During the maximal exercise test, the speed at which you breathe air in and out and the volume 
of air you breathe will be measured. Approximately once every 60 seconds during the exercise 
test, you will be prompted to breathe in completely, filling your lungs with air, and then return to 
normal breathing. Before and after the exercise test, while at rest, you will be prompted to 
perform 3 breathing maneuvers, where you complete a maximal inhalation (filling your lungs 
completely with air) followed by a complete exhalation (breathe out all the air you can). The 
133
investigators will coach you through these maneuvers. These procedures are performed during 
the maximal exercise test, and add no additional time. 
 
 
________ initial      Breathlessness Questionnaire: Following the exercise test, you will be asked 
to complete a questionnaire about the breathing sensations that you experienced during 
exercise. During this “debriefing session” we will give you a questionnaire including 15 
respiratory sensation descriptors to describe the respiratory sensations you were most often 
experiencing (e.g., respiratory work/effort, air hunger, and/or chest tightness). 
 
 
3.  Discomforts and risks: 
There are minimal risks involved with measuring/monitoring/performing: questionnaires, 
physical characteristics, body composition, activity assessment, pulmonary function testing, 
flow-volume loops, and breathlessness during exercise. 
 
EC Usage: The risks of EC use are not clear, in part, because 1) they are not regulated by the US 
Food and Drug Administration, and 2) the chemical composition varies with each brand and 
flavoring. In other words, in addition to nicotine, there will be other chemicals in the EC that re 
not disclosed by the manufacturers. However, acute usage may lead to minor throat irritation, 
cough, and dry mouth. Side effects of nicotine use may include light-headedness, nausea, and 
addiction risk. Long-term risks of EC are unknown. 
 
Maximal Aerobic Capacity Exercise Test (VO2max): VO2max test risks include abnormal heart 
beats, abnormal blood pressure responses, muscle cramps, muscle strain and/or joint injury, 
delayed muscle soreness (1 to 2 days afterwards), light headedness, fatigue, and in rare 
instances, heart attack.  
 
Loss of Confidentiality: Any time information is collected; there is a potential risk for loss of 
confidentiality.  Every effort will be made to keep your information confidential; however, this 
cannot be guaranteed.  
 
Other Risks: There may possibly be other side effects that are unknown at this time. If you are 
concerned about other, unknown side effects, please discuss this with the researchers. 
 
How you can help reduce some of the risks:  During your participation in this research, the 
researchers will closely observe your testing to determine whether there are problems that 
need medical care.  It is your responsibility to do the following: 
•  Ask questions about anything you do not understand. 
•  Keep appointments. 
•  Follow the study researchers’ instructions. 
•  Let the researchers know if your telephone number changes. 
•  Tell the researchers before you take any new medication. 
•  Tell your regular doctor about your participation in this research. 
•  Talk to a family member or friend about your participation in this research.  
4.    a. Benefits to me: You can expect to receive knowledge of your cardiovascular conditioning 
and physical fitness. You will receive a copy of your lung function data. These screenings are 
134
being performed solely for research purposes and are not to be construed as a clinical screening 
intended for diagnostic or therapeutic purposes. The screening data will not be read for any 
health care or diagnostic purpose. Under no circumstance will the investigator, research staff or 
other University employee interpret your screening as normal or abnormal and they are unable 
to make any medical comments or interpretations based on your results. Please contact your 
health care provider if you have any questions regarding this data. 
b. Potential benefits to society: The results of the study will aid in our understanding of the 
acute health effects attributed to EC and will serve as a foundation to study the long-term 
effects of EC on overall health in young adults, which are research areas recently identified 
by the National Institutes of Health. Furthermore, findings from the study could increase 
physician awareness of the effects of EC on breathlessness during exercise and may alter their 
diagnostic strategy. 
 
5.  Alternative procedures that could be utilized:  Not participating in the study. 
The procedures used in this study are frequently used in research and are the most 
appropriate methods to accomplish the goals of this research. 
 
6. Time duration of the procedures and study:   
________ initial  Pre-screening (about 20-30 min). 
You will need to visit the Charleston Forge Laboratory for the following: 
________ initial  Visit 1 (about 1.75 hours). 
________ initial  Visit 2 (about 1.25 hours). 
________ initial  Visit 3 (about 1.25 hours). 
________ initial  Visit 4 (about 1 hour). 
________ initial  Visit 5 (about 1 hour). 
 
Approximately 6.75 hours Total 
 
7. Statement of confidentiality: Volunteers are coded by an identification number for 
statistical analyses. All records are kept in a secure location. All records associated with your 
participation in the study will be subject to the university confidentiality standards and in the 
event of any publication resulting from the research no personally identifiable information 
will be disclosed. The Office of Human Research Protections in the U.S. Department of Health 
and Human Services, the U.S. Food and Drug Administration (FDA), the Office for Research 
Protections at Appalachian State University and the Institutional Review Board may review 
records related to this project. 
 
8. Right to ask questions: Please contact Jonathon Stickford, Ph.D. (828-262-7471), with 
questions, complaints, or concerns about this research. If you have any questions about 
your rights as a research subject, please contact the IRB Administrator at the Appalachian 
State University Institutional Review Board Office at (828) 262-2692, irb@appstate.edu.  
This study has been approved on 8/1/16 by the Institutional Review Board (IRB) at 
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Appalachian State University.  This approval will expire on 8/2/17 unless the IRB renews 
the approval of this research. 
  
9. Compensation: You will receive a total of $50 upon completion of this study:  
Compensation Breakdown: You will receive $10 per experimental protocol completed 
(each of Visits 2-5). Additionally, you will receive $10 upon completion of the study. Total: 
$50 
You may be asked to repeat a trial.  If you agree to repeat a trial, you will be paid for the 
repeated trial as stated above. 
 
NOTE: Current University policy requires the collection of Social Security numbers (or 
Appalachian Banner ID numbers) if study compensation is more than $100 for a single 
study or $599 for participation in multiple studies in a calendar year. Since the 
compensation for this study is not more than $100, you will not need to provide 
your address and Social Security number (or Appalachian Banner ID number) 
when you complete the form for payment. 
The University is required to annually report these payments to the IRS. This may 
require you to claim the compensation that you receive for participation in this study 
as taxable income.  
 
10. Injury Clause: In the unlikely event you become injured as a result of your participation in 
this study, standard emergency procedures will be followed. If you get hurt or sick when 
you are not at the research site, you should call your doctor or call 911 in an emergency. If 
your illness or injury could be related to the research, tell the doctors or emergency room 
staff about the research study, the name of the Principal Investigator, and provide a copy of 
this consent form if possible. Please call the PI as soon as possible (Jonathon Stickford, Ph.D. 
828-262-7471). You will be responsible for any costs for medical care not paid by your 
insurance company. No other compensation is offered by Appalachian State University.  By 
signing this document, you are not waiving any legal rights that you have against 
Appalachian State University for injury resulting from negligence of the University or its 
investigators. 
 
11. Voluntary participation: Your participation in this study is voluntary. You may withdraw 
from this study at any time by informing the research personnel. You may decline to answer 
certain questions and may decide not to comply with certain procedures. However, your 
being in the study may be contingent upon answering these questions or complying with the 
procedures. The researcher may end your role in the study without your consent if the 
researcher deems that your health or behavior adversely affects the study or increases risks 
to you beyond those approved by the Institutional Review Board and agreed upon by you in 
this document. You have been given an opportunity to ask any questions you may have, and 
all such questions or inquiries have been answered to your satisfaction. 
 
You must be 18 years of age or older to take part in this research study. If you agree to take 
part in this research study and have read the information outlined above, please sign your 
name and indicate the date below.  You will be given a copy of this signed and dated consent 
form for your records. 
 
______________________________________________ 
Volunteer      Date 
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I, the undersigned, have defined and explained the studies involved to the above volunteer. 
 
______________________________________________ 





Appendix C.: Telephone screening form 





Name: ______________________________________  
Age: _______  Sex (only males): _______   
Race: _______________ 
Phone: ______________________________    Email: ________________________ 
Address (if no email):___________________________________________ 
Height: _____ Weight: ______     Allergies (latex?):________________ 
 
Exclusion Criteria: any question answered “yes” in this section will disqualify the potential subject. 
Yes     No 
1.           Age – outside the ages of 18 and 25 yr? 
 
2.           Do you currently smoke tobacco cigarettes? 
 
3.           Have you ever been diagnosed with a sleep disorder or use CPAP? 
 
4.           Do you have a history of asthma, COPD, or any lung issues? 
 
5.           Do you have a history of an irregular heartbeat or any heart condition? 
(Have you had an EKG performed?) 
 
6.           Do you have any known health conditions?  




7.           Do you regularly exercise more than 2 times per week with a specific 
health goal in mind?  
      
 
Inclusion Criteria:   
  Yes     No 
1.           Body Mass Index of <30? 
 
2.           Are you able to ride a stationary bicycle? 
 
3.           Do you currently smoke electronic cigarettes? 
 
4.           If you don’t currently smoke electronic cigarettes, are you willing to 
smoke electronic cigarettes while participating in the study? 
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Appendix F.: 24-hour health history questionnaire 
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Appendix G.a.: Perceptual questionnaire, rating of perceived breathlessness 
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Appendix G.b.: Perceptual questionnaire, rating of unpleasantness of breathing  
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Appendix G.c.: Perceptual questionnaire, rating of perceived exertion 
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